[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 271
1. Meier C, Hoeller S, Bourgau C, Hirschmann P, Schwaller J, Went P, Pileri SA, Reiter A, Dirnhofer S, Tzankov A: Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas. Mod Pathol; 2009 Mar;22(3):476-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas.
  • The presence of JAK2 mutations in lymphomas has been addressed in larger cohorts, but there are little systemic data on numerical and structural JAK2 aberrations in lymphoid neoplasms.
  • To study the molecular epidemiology of these aberrations and the consecutive activation of the JAK2-STAT pathway in lymphomas, we examined 527 cases, covering the most common entities, in a tissue microarray by fluorescent in situ hybridization with breakable JAK2 probes, and immunohistochemistry for phosphorylated JAK2 (pJAK2) and its preferred downstream pSTAT3 and pSTAT5.
  • 9p24 gains were detected in 6/17 (35%) primary mediastinal B-cell lymphomas (PMBCLs), 25/77 (33%) Hodgkin's lymphomas (HLs), 3/16 (19%) angioimmunoblastic T-cell lymphomas (AILTs) and 1/5 ALK1(+) anaplastic large cell lymphomas (ALCLs); breaks were observed only in three cases. pJAK2 expression was most prevalent in PMBCL, peripheral T-cell lymphomas and HL. pSTAT3 predominated in ALCLs, HLs, AILTs, PMBCLs and peripheral T-cell lymphomas. pSTAT5 expression was detected frequently in follicular lymphomas, diffuse large B-cell lymphomas and AILTs.
  • In follicular lymphomas, concomitant expression of pJAK2 and pSTAT5 was linked to better prognosis, whereas expression of pSTAT3 in nongerminal center-like diffuse large B-cell lymphomas could identify a patient group with an inferior outcome.
  • Our findings stress that despite the rarity of activating JAK2 mutations in lymphomas, JAK2 is recurrently targeted by numerical, and rarely by structural, genetic aberrations in distinct lymphoma subtypes and that JAK2-STAT pathway may play a role in lymphomagenesis.
  • [MeSH-major] Janus Kinase 2 / genetics. Lymphoma / genetics. Lymphoma / metabolism. STAT Transcription Factors / metabolism. Signal Transduction / physiology

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19136931.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / STAT Transcription Factors; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


2. Maegawa RO, Hussain S, Danila DC, Teruya-Feldstein J, Maki RG, O'Connor OA: Angioimmunoblastic T-cell lymphoma with an evolving Epstein Barr virus-positive diffuse large B-cell lymphoma with unusual clinical and pathologic findings. Leuk Lymphoma; 2007 Oct;48(10):2071-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma with an evolving Epstein Barr virus-positive diffuse large B-cell lymphoma with unusual clinical and pathologic findings.
  • [MeSH-major] Herpesvirus 4, Human / metabolism. Lymphoma, B-Cell / immunology. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Large B-Cell, Diffuse / virology. Lymphoma, T-Cell, Peripheral / diagnosis. Lymphoma, T-Cell, Peripheral / virology
  • [MeSH-minor] Aged. Antigens, CD4 / biosynthesis. Antigens, CD8 / biosynthesis. Biopsy. Cell Proliferation. Diagnosis, Differential. Female. Humans. Immune System. Lymphatic Diseases / pathology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17917976.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD4; 0 / Antigens, CD8
  •  go-up   go-down


3. Welch KD, Reilly TP, Bourdi M, Hays T, Pise-Masison CA, Radonovich MF, Brady JN, Dix DJ, Pohl LR: Genomic identification of potential risk factors during acetaminophen-induced liver disease in susceptible and resistant strains of mice. Chem Res Toxicol; 2006 Feb;19(2):223-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic identification of potential risk factors during acetaminophen-induced liver disease in susceptible and resistant strains of mice.
  • Drug-induced liver disease (DILD) continues to cause significant morbidity and mortality and impair new drug development.
  • Mounting evidence suggests that DILD is a complex, multifactorial disease in which no one factor is likely to be an absolute indicator of susceptibility.
  • As an approach to better understand the multifactorial basis of DILD, we recently compared the hepatic proteomes of mice that were resistant (SJL) and susceptible (C57Bl/6) to APAP-induced liver disease (AILD) wherein we identified potential risk factors and mechanistic pathways responsible for DILD.
  • In this study, we have uncovered additional potential risk factors by comparing hepatic mRNA expression profiles of the same two strains of mice with that of SJLxB6-F1 hybrid (F1) mice, which were found to be of intermediate susceptibility to AILD.
  • One of these genes encoded for heat shock protein (HSP) 70 whose relative protein expression among the three strains of mice was found to parallel that of their mRNA levels, suggesting that this protein had a protective role against AILD.
  • However, there was no difference in the susceptibility of HSP70 knockout (KO) mice to AILD as compared to wild-type (WT) mice.
  • In support of this hypothesis, OPN KO mice were found to be more resistant to AILD than WT mice.
  • [MeSH-major] Acetaminophen / toxicity. Drug-Induced Liver Injury. Genetic Predisposition to Disease. Liver Diseases / genetics

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ACETAMINOPHEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16485898.001).
  • [ISSN] 0893-228X
  • [Journal-full-title] Chemical research in toxicology
  • [ISO-abbreviation] Chem. Res. Toxicol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Intramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HSP70 Heat-Shock Proteins; 0 / RNA, Messenger; 0 / Sialoglycoproteins; 0 / Spp1 protein, mouse; 106441-73-0 / Osteopontin; 362O9ITL9D / Acetaminophen
  •  go-up   go-down


Advertisement
4. Togashi M, Wakui H, Kodama K, Kameoka Y, Komatsuda A, Nimura T, Ichinohasama R, Sawada K: Angioimmunoblastic T-cell lymphoma and membranous nephropathy: a still unreported association. Clin Exp Nephrol; 2010 Jun;14(3):288-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma and membranous nephropathy: a still unreported association.
  • A 21-year-old man with lymphadenopathy and Coombs-positive hemolytic anemia had been treated with steroid maintenance therapy.
  • He developed nephrotic syndrome with size increase of lymphadenopathy.
  • Lymph node examination disclosed angioimmunoblastic T-cell lymphoma (AITL).
  • [MeSH-major] Glomerulonephritis, Membranous / complications. Immunoblastic Lymphadenopathy / complications. Lymphoma, T-Cell / diagnosis. Nephrotic Syndrome / etiology

  • Genetic Alliance. consumer health - Membranous nephropathy.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Rheum Dis. 2001 Mar;60(3):293-5 [11171697.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):681-91 [12780782.001]
  • [Cites] Ann Rheum Dis. 1986 Jun;45(6):519-22 [3729577.001]
  • [Cites] Clin Exp Nephrol. 2008 Dec;12(6):475-8 [18839061.001]
  • [Cites] Klin Wochenschr. 1981 May 15;59(10):509-16 [7241951.001]
  • [Cites] Medicine (Baltimore). 2007 Sep;86(5):282-92 [17873758.001]
  • [Cites] Blood. 2008 May 1;111(9):4463-70 [18292286.001]
  • [Cites] N Engl J Med. 1975 Jan 2;292(1):1-8 [1078547.001]
  • [Cites] Rinsho Ketsueki. 1991 Jul;32(7):796-801 [1920845.001]
  • [Cites] J Nephrol. 2007 May-Jun;20(3):268-87 [17557260.001]
  • [Cites] Med Pediatr Oncol. 1988;16(3):206-9 [3380062.001]
  • [Cites] Exp Mol Pathol. 2000 Apr;68(2):85-94 [10716912.001]
  • [Cites] Arch Intern Med. 1981 Sep;141(10):1373-4 [7271411.001]
  • [Cites] Am J Kidney Dis. 2002 Apr;39(4):706-12 [11920335.001]
  • [Cites] Clin Exp Nephrol. 2008 Dec;12(6):421-31 [19012046.001]
  • [Cites] Am J Clin Pathol. 1979 Jan;71(1):58-63 [420173.001]
  • [Cites] Am J Kidney Dis. 2006 Jul;48(1):e3-9 [16797380.001]
  • [Cites] Ann Hematol. 2004 Nov;83(11):731-2 [15309529.001]
  • [Cites] Am J Nephrol. 1993;13(1):73-7 [8322845.001]
  • [Cites] Nephron. 1985;39(3):275-6 [3974787.001]
  • [Cites] Arch Pathol Lab Med. 1995 Apr;119(4):377-80 [7726733.001]
  • [Cites] Ann Hematol. 2004 Jul;83(7):455-9 [15034757.001]
  • [Cites] Am J Med. 1986 Jan;80(1):63-70 [3510541.001]
  • [Cites] Nephrol Dial Transplant. 2004 Mar;19(3):574-9 [14767011.001]
  • [Cites] Acta Med Scand. 1982;211(4):319-20 [7102371.001]
  • [Cites] Am J Kidney Dis. 1993 Mar;21(3):251-9 [8447300.001]
  • [Cites] Lancet. 1974 Jun 1;1(7866):1070-3 [4135245.001]
  • [Cites] Am J Pathol. 1975 May;79(2):219-36 [1096633.001]
  • [Cites] Eur J Haematol. 2001 Sep;67(3):158-64 [11737248.001]
  • [Cites] Nihon Naika Gakkai Zasshi. 1988 Sep;77(9):1440-5 [3246561.001]
  • [Cites] Kidney Int. 1997 Jan;51(1):270-6 [8995742.001]
  • [Cites] Kidney Int Suppl. 1993 Jan;39:S71-5 [8468929.001]
  • [Cites] Nephrol Dial Transplant. 1998 Feb;13(2):453-4 [9509462.001]
  • [Cites] Dtsch Med Wochenschr. 1975 May 23;100(21):1157-63 [1132324.001]
  • (PMID = 20177729.001).
  • [ISSN] 1437-7799
  • [Journal-full-title] Clinical and experimental nephrology
  • [ISO-abbreviation] Clin. Exp. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


5. Yoshida A, Kawano Y, Kato K, Yoshida S, Yoshikawa H, Muta T, Eto T, Gondo H, Shibuya T, Ishibashi T, Yamana T: Apoptosis in perforated cornea of a patient with graft-versus-host disease. Can J Ophthalmol; 2006 Aug;41(4):472-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoptosis in perforated cornea of a patient with graft-versus-host disease.
  • CASE REPORT: Although ocular complications associated with graft-versus-host disease (GVHD) can include corneal dysfunction, corneal perforation is not common.
  • A 72-year-old man with the angioimmunoblastic type of malignant lymphoma developed chronic GVHD after allogeneic peripheral blood stem cell transplantation.
  • This revealed thinning of the epithelial cell layer and stroma, with cells, including lymphocytes, infiltrating to the site of the perforation.

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16883364.001).
  • [ISSN] 0008-4182
  • [Journal-full-title] Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
  • [ISO-abbreviation] Can. J. Ophthalmol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


6. Niino D, Kawano R, Arakawa F, Sugita Y, Suefuji N, Ohshima K: No correlation between immunoglobulin heavy chain rearrangements and the prognosis of angioimmunoblastic T-cell lymphoma. Eur J Haematol; 2009 Aug;83(2):159-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No correlation between immunoglobulin heavy chain rearrangements and the prognosis of angioimmunoblastic T-cell lymphoma.
  • [MeSH-major] Gene Rearrangement, B-Lymphocyte / genetics. Immunoblastic Lymphadenopathy / genetics. Immunoglobulin Heavy Chains / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Clone Cells / metabolism. Humans. Lymphoma, T-Cell / diagnosis. Middle Aged. Polymerase Chain Reaction. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19467019.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


7. Khong PL, Pang CB, Liang R, Kwong YL, Au WY: Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies. Ann Hematol; 2008 Aug;87(8):613-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies.
  • Fluorine-18 fluorodeoxyglucose (FDG)-positron emission tomography (PET) is useful in Hodgkin and B-cell lymphomas.
  • Few data exist on T-cell and natural killer (NK)-cell lymphomas.
  • Thirty consecutive T-cell and NK-cell lymphomas were investigated with PET-computerized tomography (CT).
  • In 12 NK-cell lymphomas, all nasal/extranasal lesions were FDG-avid.
  • In two NK-cell lymphomas, PET did not detect morphologically occult marrow infiltration uncovered by in situ hybridisation for Epstein-Barr-virus-encoded small RNA.
  • In angioimmunoblastic lymphoma (n = 7), peripheral T-cell lymphoma, unspecified (PTCL-U, n = 4) and anaplastic large cell lymphoma (ALCL, n = 3), involved nodal/extranodal sites shown on CT and/or biopsy were concordantly PET-positive.
  • In one case of T-cell large granular lymphocyte leukaemia, marrow, nodal and bowel infiltrations were not FDG-avid.
  • These observations defined the pre-treatment value of PET-CT in T-cell and NK-cell lymphomas.
  • [MeSH-major] Fluorodeoxyglucose F18. Killer Cells, Natural / radionuclide imaging. Lymphoma, T-Cell / radionuclide imaging. Positron-Emission Tomography
  • [MeSH-minor] Adolescent. Adult. Aged. Cohort Studies. Disease Progression. Female. Humans. Male. Middle Aged

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18509641.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


8. Balagué O, Martínez A, Colomo L, Roselló E, Garcia A, Martínez-Bernal M, Palacín A, Fu K, Weisenburger D, Colomer D, Burke JS, Warnke RA, Campo E: Epstein-Barr virus negative clonal plasma cell proliferations and lymphomas in peripheral T-cell lymphomas: a phenomenon with distinctive clinicopathologic features. Am J Surg Pathol; 2007 Sep;31(9):1310-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus negative clonal plasma cell proliferations and lymphomas in peripheral T-cell lymphomas: a phenomenon with distinctive clinicopathologic features.
  • Clonal B-cell populations have been described in peripheral T-cell lymphomas (PTCL) as secondary Epstein-Barr virus (EBV) driven B-cell expansions that may evolve to an overt B-cell lymphoma.
  • EBV-negative B-cell proliferations associated with T-cell lymphomas are uncommon and not well characterized.
  • We studied 15 patients who developed an EBV-negative B-cell proliferation or malignant lymphoma associated with PTCL.
  • The T-cell tumors were 8 PTCL, not otherwise specified, 4 angioimmunoblastic T-cell lymphomas, and 3 cutaneous PTCL.
  • The B-cell component was intermingled with the PTCL in all patients and it was classified as clonal/monotypic plasma cell proliferation in 8 lesions, clonal/monotypic large B-cell proliferation in 4 patients, and B-cell lymphoma with plasmacytic/plasmablastic differentiation in 3 patients.
  • Two patients had 2 clonally unrelated plasma cell proliferations associated with the same PTCL.
  • Clonal IgH and T-cell receptor rearrangements were detected in 11/12 and 11/13 cases examined, respectively.
  • Sequential samples in 7 patients showed persistence of the PTCL and the B-cell component in 4, the PTCL without the B-cell lymphoma in 2, and progression of the B-cell neoplasm in 1.
  • In conclusion, EBV-negative clonal or mononotypic B-cell proliferations in patients with PTCL present with a spectrum of lesions ranging from plasma cell proliferations to overt lymphomas with plasmacytic/plasmablastic features.
  • [MeSH-major] Cell Proliferation. Herpesvirus 4, Human. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, T-Cell, Peripheral / pathology. Plasma Cells / pathology
  • [MeSH-minor] Adolescent. Aged. Aged, 80 and over. Cell Differentiation. Clone Cells / pathology. Clone Cells / virology. Cytomegalovirus. Female. Gene Expression Regulation, Neoplastic. Gene Rearrangement, B-Lymphocyte. Gene Rearrangement, T-Lymphocyte. Herpesvirus 8, Human. Humans. Male. Middle Aged

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721185.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


9. Krivolapov IuA: [Histological and immunophenotypical characteristics of peripheral T-cell lymphomas]. Arkh Patol; 2005 Mar-Apr;67(2):17-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Histological and immunophenotypical characteristics of peripheral T-cell lymphomas].
  • Histopathologic features of immunohistochemically confirmed 37 nodal peripheral T-cell lymphomas are described.
  • Unspecified and 10 angioimmunoblastic T-cell lymphomas were analyzed.
  • The most demonstrative histological features of both types of lymphomas were spectrum of small, medium and large lymphoid cells, lymphoid cells with irregular nuclei, presence of clusters of clear cells, arborizing endothelial venules, increased number of histiocytes, eosinophils and plasma cells.
  • Delineation between peripheral T-cell lymphoma, unspecified and angioimmunoblastic T-cell lymphoma needs evaluation of follicular dendritic cell pattern.
  • The results suggest that detection of histopathologic features typical for peripheral T-cell lymphomas gives an opportunity to compose optimal panel for immunotyping which is absolutely necessary.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / immunology. Lymphoma, T-Cell, Peripheral / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15938113.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


10. Omura H, Nagata N, Wakamatsu K, Minami T, Taguchi K, Okamura K, Ono S, Katahira K, Maki S, Akasaki T: [Case of angioimmunoblastic T-cell lymphoma with eosinophilia and interstitial shadows]. Nihon Kokyuki Gakkai Zasshi; 2010 Nov;48(11):831-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case of angioimmunoblastic T-cell lymphoma with eosinophilia and interstitial shadows].
  • A 76-year-old woman was admitted because of respiratory failure with bilateral multiple interstitial shadows and mediastinal adenopathy on chest CT images.
  • Corticosteroids were administered before diagnosis because of rapid respiratory failure.
  • A definitive diagnosis was not obtained until bronchofiberoptic examination.
  • At the time of recurrence 6 months later, angioimmunoblastic T-cell lymphoma (AITL) was diagnosed with axillary lymph node biopsy.
  • Lymph node biopsy is necessary to establish a definitive diagnosis.
  • [MeSH-major] Eosinophilia / complications. Immunoblastic Lymphadenopathy / complications. Immunoblastic Lymphadenopathy / diagnosis. Lung Diseases, Interstitial / complications
  • [MeSH-minor] Aged. Axilla. Biopsy. Diagnosis, Differential. Female. Humans. Lymph Nodes / pathology. Mediastinum. Radiography, Thoracic. Respiratory Insufficiency / etiology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Eosinophilic Disorders.
  • MedlinePlus Health Information. consumer health - Interstitial Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21141062.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


11. Marsee DK, Pinkus GS, Hornick JL: Podoplanin (D2-40) is a highly effective marker of follicular dendritic cells. Appl Immunohistochem Mol Morphol; 2009 Mar;17(2):102-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The monoclonal antibody D2-40 recognizes the membrane protein podoplanin, which is an established marker for germ cell tumors, mesotheliomas, and other tumor types and is also expressed in a variety of normal cells including follicular dendritic cells (FDCs).
  • Paraffin sections of 26 lymph nodes were analyzed, including 4 cases of nodular lymphocyte-predominant Hodgkin lymphoma, 4 angioimmunoblastic T-cell lymphoma, 8 follicular lymphoma (including 3 cases with a component of diffuse large B-cell lymphoma), 5 hyaline-vascular Castleman disease, and 5 reactive lymph nodes with follicular hyperplasia.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18838918.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers, Tumor; 0 / CLU protein, human; 0 / CR1 protein, human; 0 / Clusterin; 0 / Membrane Glycoproteins; 0 / PDPN protein, human; 0 / Receptors, Complement 3b; 0 / Receptors, Complement 3d; 0 / monoclonal antibody D2-40
  •  go-up   go-down


12. d'Amore F, Radford J, Relander T, Jerkeman M, Tilly H, Osterborg A, Morschhauser F, Gramatzki M, Dreyling M, Bang B, Hagberg H: Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma. Br J Haematol; 2010 Sep;150(5):565-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma.
  • The efficacy and safety of zanolimumab (HuMax-CD4) in patients with relapsed or refractory peripheral T Cell lymphoma (PTCL) was evaluated.
  • Twenty-one adult patients with relapsed or refractory CD4(+) PTCL of non-cutaneous type (angioimmunoblastic T cell lymphoma (AITL) n = 9, PTCL-not otherwise specified (NOS) n = 7, anaplastic large cell lymphoma (ALCL) n = 4 and enteropathy type T cell lymphoma n = 1) were treated in a single-arm multi-centre study, with weekly intravenous infusions of zanolimumab 980 mg for 12 weeks.
  • Seventeen of the patients had advanced stage disease (Ann Arbor stages III-IV).
  • Responses were obtained in different PTCL entities: AITL (n = 3), ALCL (n = 1) and PTCL-NOS (n = 1).
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, T-Cell, Peripheral / drug therapy

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20629661.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / zanolimumab
  •  go-up   go-down


13. Sonnen R, Schmidt WP, Müller-Hermelink HK, Schmitz N: The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Haematol; 2005 May;129(3):366-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas.
  • The World Health Organization (WHO) lymphoma classification recognises anaplastic large cell lymphoma (ALCL), angioimmunoblastic lymphoma (AIL) and peripheral T-cell lymphoma, unspecified (PTCU) as nodal mature T-cell lymphomas.
  • Little is known about long-term outcome and prognostic factors of these diseases.
  • To a large extent, the IPI score explains the differences in survival between histological subtypes of nodal mature T-cell lymphomas.
  • The IPI may therefore be used for risk stratification in clinical trials to identify patients who would benefit most from new treatment strategies, such as high-dose chemotherapy followed by stem cell or bone marrow transplantation.
  • [MeSH-major] Lymphoma, T-Cell / diagnosis. Severity of Illness Index
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Bone Marrow Transplantation. Cause of Death. Epidemiologic Methods. Female. Hematopoietic Stem Cell Transplantation. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / therapy. Lymphoma, T-Cell, Peripheral / diagnosis. Lymphoma, T-Cell, Peripheral / therapy. Male. Middle Aged. Neoplasms, Second Primary. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15842660.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Jones B, Vun Y, Sabah M, Egan CA: Toxic epidermal necrolysis secondary to angioimmunoblastic T-cell lymphoma. Australas J Dermatol; 2005 Aug;46(3):187-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxic epidermal necrolysis secondary to angioimmunoblastic T-cell lymphoma.
  • A 67-year-old man presented with a history of lymphadenopathy, fevers and separate skin eruptions of erythrodermic spongiotic dermatitis initially and subsequent toxic epidermal necrolysis.
  • Initial lymph node biopsies showed non-specific granulomatous changes, and skin biopsies and bone marrow aspirate were not diagnostic.
  • Due to persisting lymphadenopathy, further lymph node biopsy led to the diagnosis of angioimmunoblastic T-cell lymphoma, a rare form of peripheral T-cell lymphoma with a poor prognosis.
  • At the time of diagnosis his condition deteriorated rapidly and he died soon after.
  • [MeSH-major] Head and Neck Neoplasms / complications. Immunoblastic Lymphadenopathy / complications. Lymphoma, T-Cell / complications. Stevens-Johnson Syndrome / etiology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16008654.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Immunoglobulins, Intravenous
  •  go-up   go-down


15. Cuadros M, Dave SS, Jaffe ES, Honrado E, Milne R, Alves J, Rodríguez J, Zajac M, Benitez J, Staudt LM, Martinez-Delgado B: Identification of a proliferation signature related to survival in nodal peripheral T-cell lymphomas. J Clin Oncol; 2007 Aug 1;25(22):3321-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a proliferation signature related to survival in nodal peripheral T-cell lymphomas.
  • PURPOSE: Nodal peripheral T-cell lymphomas (PTCLs) constitute a heterogeneous group of neoplasms, suggesting the existence of molecular differences contributing to their histologic and clinical variability.
  • Initial expression profiling studies of T-cell lymphomas have been inconclusive in yielding clinically relevant insights.
  • MATERIALS AND METHODS: We analyzed the expression profiles of 35 nodal PTCLs (23 PTCLs unspecified and 12 angioimmunoblastic) using two different microarray platforms, the cDNA microarray developed at the Spanish National Cancer Centre and an oligonucleotide microarray.
  • Genes in these clusters seemed to be functionally related to different cellular processes such as proliferation, inflammatory response, and T-cell or B-cell lineages.
  • This proliferation signature included genes commonly associated with the cell cycle, such as CCNA, CCNB, TOP2A, and PCNA.
  • [MeSH-major] Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. Lymph Nodes / pathology. Lymphoma, T-Cell / genetics. Lymphoma, T-Cell / mortality


16. Miyazaki K, Yamaguchi M, Imai H, Kobayashi T, Tamaru S, Nishii K, Yuda M, Shiku H, Katayama N: Gene expression profiling of peripheral T-cell lymphoma including gammadelta T-cell lymphoma. Blood; 2009 Jan 29;113(5):1071-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling of peripheral T-cell lymphoma including gammadelta T-cell lymphoma.
  • The gene expression profile of peripheral gammadelta T-cell lymphoma (gammadeltaTCL) has not been investigated.
  • Using oligonucleotide microarrays, we analyzed total RNA from 7 patients with gammadeltaTCL (4 hepatosplenic, 1 cutaneous, 1 intestinal, and 1 thyroidal) and 27 patients with alphabetaTCL (11 peripheral TCL-unspecified, 15 angioimmunoblastic TCL, and 1 hepatosplenic).
  • We identified a T-cell receptor signature gene set, which accurately classified gammadeltaTCL and alphabetaTCL.
  • One case of hepatosplenic alphabetaTCL was placed in the gammadeltaTCL grouping. gammadeltaTCL signature genes included genes encoding killer cell immunoglobulin-like receptors and killer cell lectin-like receptors.
  • Our results indicate that hepatosplenic gammadeltaTCL is a distinct form of peripheral TCL and suggest that nonhepatosplenic gammadeltaTCLs are heterogeneous in gene expression.
  • [MeSH-major] Gene Expression Regulation, Leukemic. Lymphoma, T-Cell / metabolism. Neoplasm Proteins / biosynthesis. Receptors, Antigen, T-Cell, gamma-delta

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18955564.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Receptors, Antigen, T-Cell, gamma-delta
  •  go-up   go-down


17. Naresh KN, Menasce LP, Shenjere P, Banerjee SS: 'Precursors' of classical Hodgkin lymphoma in samples of angioimmunoblastic T-cell lymphoma. Br J Haematol; 2008 Apr;141(1):124-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 'Precursors' of classical Hodgkin lymphoma in samples of angioimmunoblastic T-cell lymphoma.
  • [MeSH-major] Hodgkin Disease / pathology. Lymphoma, T-Cell, Peripheral / pathology. Neoplastic Stem Cells / pathology
  • [MeSH-minor] Aged. Epstein-Barr Virus Infections / complications. Humans. Immunoblastic Lymphadenopathy / pathology. Male

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18324974.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


18. Lee Y, Lee KW, Kim JH, Bang SM, Lee JS, Park BB, Kim WS, Suh C, Kang JH, Ryoo BY, Lee JH, Shin DB: Epstein-Barr virus-positivity in tumor has no correlation with the clinical outcomes of patients with angioimmunoblastic T-cell lymphoma. Korean J Intern Med; 2008 Mar;23(1):30-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus-positivity in tumor has no correlation with the clinical outcomes of patients with angioimmunoblastic T-cell lymphoma.
  • BACKGROUND/AIMS: Epstein-Barr virus (EBV) is involved in the pathogenesis of angioimmunoblastic T-cell lymphoma (AILT), but its precise role and prognostic impact are not clear.
  • This study aimed to evaluate the incidence of EBV-postitivity in the tumor and bone marrow (BM) samples from AILT patients, and their correlations with the clinical variables and patient survival.
  • METHODS: Seventy AILT cases were identified over a period of 8 years.
  • In 13 (48%) patients, gross tumor involvement was recognized by hematoxylin-eosin staining at the time of diagnosis.
  • CONCLUSIONS: EBV-positivity of tumor had no impact on the prognosis of AILT patients.
  • [MeSH-major] Herpesvirus 4, Human / isolation & purification. Immunoblastic Lymphadenopathy / virology. Lymphoma, T-Cell / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2000 Feb;156(2):661-9 [10666395.001]
  • [Cites] Am J Clin Pathol. 2007 Jun;127(6):860-8 [17509983.001]
  • [Cites] Am J Clin Pathol. 2000 Aug;114(2):236-47 [10941339.001]
  • [Cites] Am J Clin Pathol. 2002 Mar;117(3):368-79 [11888076.001]
  • [Cites] Leuk Lymphoma. 2002 Apr;43(4):805-11 [12153168.001]
  • [Cites] Int J Cancer. 2003 Jan 1;103(1):12-20 [12455048.001]
  • [Cites] Lancet Infect Dis. 2003 Mar;3(3):131-40 [12614729.001]
  • [Cites] N Engl J Med. 2004 Mar 25;350(13):1328-37 [15044644.001]
  • [Cites] J Korean Med Sci. 2004 Apr;19(2):229-33 [15082896.001]
  • [Cites] Ann Oncol. 2004 Oct;15(10):1467-75 [15367405.001]
  • [Cites] Int J Cancer. 1976 Feb 15;17(2):177-81 [175027.001]
  • [Cites] Blood. 1991 Feb 15;77(4):799-808 [1847084.001]
  • [Cites] Blood. 1992 Apr 1;79(7):1789-95 [1373088.001]
  • [Cites] Blood. 1992 Jul 15;80(2):484-91 [1320954.001]
  • [Cites] Blood. 1992 Oct 1;80(7):1804-12 [1327284.001]
  • [Cites] Histopathology. 1993 Feb;22(2):145-9 [8384155.001]
  • [Cites] Ann Oncol. 1995 Sep;6(7):659-64 [8664186.001]
  • [Cites] Haematologica. 2005 Aug;90(8):1063-9 [16079105.001]
  • [Cites] Haematologica. 2005 Sep;90(9):1192-6 [16154842.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:260-6 [16304390.001]
  • [Cites] J Mol Diagn. 2006 Sep;8(4):466-75; quiz 527 [16931587.001]
  • [Cites] Leuk Lymphoma. 2007 Apr;48(4):716-22 [17454629.001]
  • [Cites] N Engl J Med. 2000 Aug 17;343(7):481-92 [10944566.001]
  • (PMID = 18363277.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / DNA, Viral
  • [Other-IDs] NLM/ PMC2686953
  •  go-up   go-down


19. Greer JP: Therapy of peripheral T/NK neoplasms. Hematology Am Soc Hematol Educ Program; 2006;:331-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy of peripheral T/NK neoplasms.
  • The mature T/natural killer (NK) lymphoma/leukemias represent 5-15% of all non-Hodgkin lymphoma.
  • These diseases have a geographic variation, with more nodal disease in North America and Europe, including peripheral T cell lymphomas, unspecified, anaplastic large cell lymphoma, and angioimmunoblastic T cell lymphoma; and more extranodal disease in Asia due to Epstein-Barr virus-related nasal NK/T lymphoma and human T-cell leukemia virus (HTLV)-1-associated adult T cell leukemia/lymphoma.
  • The prognosis in most peripheral T/NK neoplasms is poor, with 5-year survival less than 30%.
  • Progress has been slow due to the rarity of the diseases, geographic variation, relative chemoresistance, and lack of randomized trials.
  • In this review, topics include the question of CHOP as standard therapy, prognostic factors, disease-adapted therapy, novel approaches, monoclonal antibody therapy, and stem cell transplantation.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17124080.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 46
  •  go-up   go-down


20. Drakos E, Rassidakis GZ, Tsioli P, Lai R, Jones D, Medeiros LJ: Differential expression of WT1 gene product in non-Hodgkin lymphomas. Appl Immunohistochem Mol Morphol; 2005 Jun;13(2):132-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of WT1 gene product in non-Hodgkin lymphomas.
  • However, WT1 expression in non-Hodgkin lymphomas (NHLs) has not been studied.
  • The authors assessed for WT1 expression in six lymphoma/leukemia cell lines using Western blot methods after subcellular fractionation.
  • The B-cell NHLs analyzed were 18 diffuse large B-cell lymphomas, 13 marginal zone B-cell lymphomas, 9 small lymphocytic lymphomas, (DLBCLs), 8 follicular lymphomas, 6 mantle cell lymphomas, 5 Burkitt lymphomas, 3 lymphoplasmacytic lymphomas, and 2 B-cell lymphoblastic lymphomas.
  • The T-cell NHLs analyzed were 43 anaplastic large cell lymphomas (ALCLs), 26 peripheral T-cell lymphomas unspecified, 13 angioimmunoblastic T-cell lymphomas, 6 cutaneous ALCLs, 6 cases of mycosis fungoides, 5 extranodal NK/T-cell lymphomas of nasal type, and 4 T-cell lymphoblastic lymphomas.
  • WT1 levels were higher in cytoplasmic extracts than in nuclear extracts of the Karpas 299 and SU-DHL-1 lymphoma cell lines but were higher in nuclear extracts than in the cytoplasmic extracts of the Jurkat, HH, U-937, and K562 leukemia cell lines.
  • In NHLs, WT1 was positive in 4 of 5 (80%) Burkitt lymphomas, 9 of 12 (75%) ALK-positive ALCLs, 3 of 6 (50%) lymphoblastic lymphomas (2 of 4 T-cell, 1 of 2 B-cell), 14 of 31 (45%) ALK-negative ALCLs, 6 of 18 (33%) DLBCLs, and 1 of 6 (17%) cutaneous ALCLs.
  • WT1 immunoreactivity was primarily cytoplasmic in all positive NHLs except T-cell lymphoblastic lymphoma.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15894924.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / WT1 Proteins
  •  go-up   go-down


21. Strupp C, Germing U, Aivado M, Kündgen A, Fenk R, Hünerlitürkoglu A, Kobbe G, Haas R, Gattermann N: The ratio between CD4+ and CD8+ cells in the peripheral blood of patients with hematological malignancies is not altered by thalidomide. Leuk Lymphoma; 2005 Jul;46(7):999-1006
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The ratio between CD4+ and CD8+ cells in the peripheral blood of patients with hematological malignancies is not altered by thalidomide.
  • Thalidomide is thought to have anti-angiogenic and immunomodulatory properties, including suppression of tumor necrosis factor-alpha, effects on interleukins and interferons, down-regulation of some cell adhesion molecules, and changes in the proportion of lymphocyte subsets.
  • We examined the effect of thalidomide on T-lymphocyte subsets in 18 patients with MDS, 6 patients with MM, 4 patients with IM, and 3 patients with angioimmunoblastic lymphoma (AILD).
  • These patients had either a relapse or progressive disease following cytotoxic chemotherapy including high-dose chemotherapy with autologous stem cell support.
  • T-lymphocyte subsets (CD4+, CD8+) were measured by fluorescence-activated cell sorter (FACS) before and during treatment with thalidomide.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. CD4-CD8 Ratio. Hematologic Diseases / drug therapy. Immunosuppressive Agents / therapeutic use. Thalidomide / therapeutic use
  • [MeSH-minor] Adult. Aged. CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Female. Humans. Male. Middle Aged. Stem Cell Transplantation

  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019550.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Immunosuppressive Agents; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


22. Bruns I, Fox F, Reinecke P, Kobbe G, Kronenwett R, Jung G, Haas R: Complete remission in a patient with relapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab. Leukemia; 2005 Nov;19(11):1993-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission in a patient with relapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, T-Cell / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16151464.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


23. Rodríguez Pinilla SM, Roncador G, Rodríguez-Peralto JL, Mollejo M, García JF, Montes-Moreno S, Camacho FI, Ortiz P, Limeres-González MA, Torres A, Campo E, Navarro-Conde P, Piris MA: Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma expresses follicular T-cell markers. Am J Surg Pathol; 2009 Jan;33(1):81-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma expresses follicular T-cell markers.
  • Cutaneous CD4 small/medium-sized pleomorphic T-cell lymphoma (CSTCL) is a cutaneous T-cell lymphoma defined by a predominance of small-to-medium-sized CD4 pleomorphic T cells, with a favorable clinical course.
  • We report for the first time the expression of PD-1 and other TFH cell markers in CSTCLs and discuss its biologic significance.
  • Sixteen CSTCLs were included in this study, and also 20 reactive inflammatory conditions, 10 primary cutaneous marginal zone, 10 follicular center lymphomas, and 5 primary CD30 cutaneous lymphomas.
  • Clonal Ig and T-cell receptor rearrangements and Epstein-Barr virus-encoded RNA expression were also evaluated.
  • Morphologic and clinical data were reviewed.
  • A dominant T-cell clone was identified in 14 cases, whereas polymerase chain reaction IgH gene rearrangement studies showed that all cases were polyclonal.
  • None of the patients had lymphadenopathy or showed any evidence of systemic disease, nor did they have any previous history of mycosis fungoides or drug reactions.
  • FTH cell markers are not exclusive to angioimmunoblastic lymphadenopathy but may also be seen in neoplastic cells of CSTCLs.
  • Moreover, these findings suggest that B-cell stimulation by FTH could also take place in some cutaneous T-cell lymphomas.
  • [MeSH-major] Biomarkers, Tumor / analysis. Lymphoma, T-Cell / immunology. Skin Neoplasms / immunology. T-Lymphocytes, Helper-Inducer / immunology
  • [MeSH-minor] Adult. Aged. Antigens, CD / biosynthesis. Apoptosis Regulatory Proteins / biosynthesis. Chemokine CXCL13 / biosynthesis. DNA-Binding Proteins / biosynthesis. Female. Fluorescent Antibody Technique. Gene Rearrangement, B-Lymphocyte. Gene Rearrangement, T-Lymphocyte. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. Polymerase Chain Reaction. Programmed Cell Death 1 Receptor

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18987541.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Apoptosis Regulatory Proteins; 0 / BCL6 protein, human; 0 / Biomarkers, Tumor; 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 0 / DNA-Binding Proteins; 0 / PDCD1 protein, human; 0 / Programmed Cell Death 1 Receptor
  •  go-up   go-down


24. Todd T, Erber W: Diagnosis of leukaemic phase of angioimmunoblastic T-cell lymphoma from the peripheral blood. Br J Haematol; 2006 Jul;134(2):124
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of leukaemic phase of angioimmunoblastic T-cell lymphoma from the peripheral blood.
  • [MeSH-major] Immunoblastic Lymphadenopathy / diagnosis. Lymphoma, T-Cell, Peripheral / diagnosis

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16764685.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD2; 0 / Biomarkers, Tumor; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


25. Tan BT, Warnke RA, Arber DA: The frequency of B- and T-cell gene rearrangements and epstein-barr virus in T-cell lymphomas: a comparison between angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified with and without associated B-cell proliferations. J Mol Diagn; 2006 Sep;8(4):466-75; quiz 527
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The frequency of B- and T-cell gene rearrangements and epstein-barr virus in T-cell lymphomas: a comparison between angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified with and without associated B-cell proliferations.
  • We report on a series of 58 cases of angioimmunoblastic T-cell lymphoma (AILT) and 59 cases of peripheral T-cell lymphoma, unspecified (PTCL-NOS).
  • Subsets of cases from both diagnostic groups were complicated by associated B-cell proliferations, and we performed B- and T-cell clonality studies and in situ hybridization for Epstein-Barr virus (EBV) to investigate the relationship between B-cell proliferation, B-cell clonality, and EBV.
  • Using multiplex polymerase chain reaction assays based on the BIOMED-2 collaborative study, we detected TCRgamma T-cell clones in 78 and 81% of AILT and PTCL-NOS cases, respectively, and IGH B-cell clones in 34 and 35% of AILT and PTCL-NOS cases, respectively.
  • The majority of cases contained EBV-positive cells, including 50% of AILT and 57% of PTCL-NOS cases, and cases with B-cell proliferations were more often EBV-positive.
  • Although a relatively high rate of B-cell clonality has been shown for AILT, our findings for PTCL-NOS differ from previous reports in that B-cell clonality was relatively frequent.
  • Overall, a positive B-cell clone correlated, in part, with the presence of a B-cell proliferation but not with EBV.
  • Our findings demonstrate that B-cell clonality is a common finding in AILT and PTCL-NOS, and its presence should not negate the diagnosis established by morphologic, immunophenotypic, and clinical findings.
  • [MeSH-major] Gene Rearrangement, B-Lymphocyte. Gene Rearrangement, T-Lymphocyte. Herpesvirus 4, Human / genetics. Lymphoma, T-Cell / genetics. Lymphoma, T-Cell, Peripheral / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Cell Proliferation. Clone Cells. Female. Humans. Immunoglobulin Heavy Chains / genetics. Male. Middle Aged. Receptors, Antigen, T-Cell, gamma-delta / genetics

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mol Diagn. 2001 Nov;3(4):133-40 [11687596.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):661-9 [10666395.001]
  • [Cites] Am J Clin Pathol. 2002 Mar;117(3):368-79 [11888076.001]
  • [Cites] J Mol Diagn. 2002 May;4(2):81-9 [11986398.001]
  • [Cites] J Pathol. 2002 Oct;198(2):171-80 [12237876.001]
  • [Cites] Leukemia. 2002 Oct;16(10):2134-41 [12357368.001]
  • [Cites] Int J Cancer. 2003 Jan 1;103(1):12-20 [12455048.001]
  • [Cites] Am J Clin Pathol. 2002 Dec;118(6):848-54 [12472277.001]
  • [Cites] Leuk Lymphoma. 2003 Jan;44(1):117-21 [12691150.001]
  • [Cites] J Mol Diagn. 2003 May;5(2):82-7 [12707372.001]
  • [Cites] Leuk Lymphoma. 2003 May;44(5):807-13 [12802918.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Blood. 1983 Jun;61(6):1138-45 [6404327.001]
  • [Cites] Blood. 1986 Jan;67(1):1-11 [3079640.001]
  • [Cites] Am J Clin Pathol. 1986 Apr;85(4):490-3 [2420169.001]
  • [Cites] Leukemia. 1987 Mar;1(3):235 [3669744.001]
  • [Cites] Am J Pathol. 1988 Dec;133(3):549-56 [2849301.001]
  • [Cites] Clin Chim Acta. 1991 Apr;198(1-2):93-174 [1863986.001]
  • [Cites] Blood. 1992 Apr 1;79(7):1789-95 [1373088.001]
  • [Cites] Histopathology. 1993 Feb;22(2):145-9 [8384155.001]
  • [Cites] Blood. 1993 Jul 1;82(1):217-23 [8391874.001]
  • [Cites] Histopathology. 1994 Feb;24(2):115-22 [8181803.001]
  • [Cites] Blood. 1994 Jul 15;84(2):574-81 [8025283.001]
  • [Cites] Virchows Arch. 1994;424(6):593-600 [8055152.001]
  • [Cites] J Pathol. 1994 Dec;174(4):233-42 [7884584.001]
  • [Cites] Leuk Lymphoma. 1995 Sep;19(1-2):1-12 [8574154.001]
  • [Cites] J Clin Pathol. 1995 Nov;48(11):1045-50 [8543629.001]
  • [Cites] Am J Surg Pathol. 1998 Aug;22(8):956-64 [9706975.001]
  • [Cites] J Pathol. 1998 May;185(1):79-85 [9713363.001]
  • [Cites] Mol Diagn. 1999 Jun;4(2):119-33 [10462627.001]
  • [Cites] Hematol Oncol. 2004 Dec;22(4):169-77 [16134192.001]
  • [Cites] J Mol Diagn. 2005 Oct;7(4):495-503 [16237219.001]
  • [Cites] Am J Clin Pathol. 2000 Aug;114(2):236-47 [10941339.001]
  • [Cites] Mod Pathol. 2000 Dec;13(12):1269-79 [11144922.001]
  • [Cites] Diagn Mol Pathol. 2001 Jun;10(2):69-77 [11385314.001]
  • [Cites] Blood. 2002 Jan 15;99(2):627-33 [11781247.001]
  • [CommentIn] J Mol Diagn. 2006 Sep;8(4):426-9; quiz 526-7 [16931581.001]
  • (PMID = 16931587.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Receptors, Antigen, T-Cell, gamma-delta
  • [Other-IDs] NLM/ PMC1867616
  •  go-up   go-down


26. Kawano R, Ohshima K, Wakamatsu S, Suzumiya J, Kikuchi M, Tamura K: Epstein-Barr virus genome level, T-cell clonality and the prognosis of angioimmunoblastic T-cell lymphoma. Haematologica; 2005 Sep;90(9):1192-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus genome level, T-cell clonality and the prognosis of angioimmunoblastic T-cell lymphoma.
  • BACKGROUND AND OBJECTIVES: Angioimmunoblastic T-cell lymphoma (AILT) is a peripheral T-cell tumor of unknown etiology with variable biological and clinical presentations.
  • Previous clonality studies have shown heterogeneous clonal restrictions of B- and T-cell populations in this tumor.
  • AILT is characterized by the presence of increased numbers of Epstein-Barr virus (EBV) infected cells.
  • DESIGN AND METHODS: Frozen material from 59 cases of AILT was used for DNA isolation and gene analysis by Southern blotting.
  • Survival rate did not correlate with either T-cell clonality (p=0.84), or presence of EBV-infected cells (p=0.84).
  • The EBV-DNA copy number in EBV-infected tissue did not correlate with disease progression (p=0.87).
  • The survival rate and clinical status according to the international prognostic index (IPI) did not correlate with T-cell clonality status or EBV infection.
  • INTERPRETATION AND CONCLUSIONS: AILT remains a heterogeneous disease with clinical behavior that varies irrespective of the genomic parameters investigated.
  • [MeSH-major] Genome, Viral. Herpesvirus 4, Human / genetics. Immunoblastic Lymphadenopathy / genetics. Immunoblastic Lymphadenopathy / virology. Lymphoma, T-Cell / genetics. Lymphoma, T-Cell / virology. T-Lymphocytes / immunology. T-Lymphocytes / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16154842.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


27. Lin P, Hao S, Handy BC, Bueso-Ramos CE, Medeiros LJ: Lymphoid neoplasms associated with IgM paraprotein: a study of 382 patients. Am J Clin Pathol; 2005 Feb;123(2):200-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (LPL/WM) was most common, 225 cases (median serum IgM level, 2.2 g/dL; range, 0.2-10.9 g/dL).
  • For 157 cases, classification and median (and range in g/dL) IgM levels were as follows: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; n = 77), 0.9 (0.1-2.1); marginal zone lymphoma (n = 27), 0.5 (0.1-2.4); follicular lymphoma (n = 18), 0.4 (0.1-1.6); mantle cell lymphoma (n = 11), 0.4 (0.2-1.3); diffuse large B-cell lymphoma (DLBCL; n = 7), 0.5 (0.2-1.0); DLBCL associated with low-grade lymphoma (n = 5), 0.9 (0.4-3.0); angioimmunoblastic T-cell lymphoma (n = 4), 0.8 (0.8); and CD5+CD23- low-grade B-cell lymphoma, unclassified (n = 8), 0.5 (0.3-2.9).
  • Thus, serum IgM paraprotein level is not a reliable discriminator in differential diagnosis.
  • [MeSH-major] Immunoglobulin M / blood. Leukemia / complications. Lymphoma / complications. Paraproteinemias / complications. Paraproteins / immunology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15842043.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin M; 0 / Paraproteins
  •  go-up   go-down


28. Kyriakou C, Canals C, Goldstone A, Caballero D, Metzner B, Kobbe G, Kolb HJ, Kienast J, Reimer P, Finke J, Oberg G, Hunter A, Theorin N, Sureda A, Schmitz N, Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation: High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol; 2008 Jan 10;26(2):218-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
  • PURPOSE: Patients with angioimmunoblastic T-cell lymphoma (AITL) have poor prognoses with current conventional chemotherapy.
  • The aim of this study was to evaluate the effect of high-dose therapy (HDT) followed by autologous stem-cell transplantation (ASCT) on patients with AITL.
  • The source of the stem cells was peripheral blood in 143 patients.
  • Forty-two patients died as a result of disease progression, and nine died as a result of regimen-related toxicity.
  • Disease status at transplantation was the major factor that impacted outcome.
  • The estimated PFS rates for patients who received their transplants in CR were 70% and 56% at 24 and 48 months, respectively; 42% and 30% for patients with chemotherapy-sensitive disease at those time points, respectively; and 23% at both time points for patients with chemotherapy-refractory disease.
  • CONCLUSION: This study shows that HDT and ASCT offers the possibility of long-term disease-free survival to patients with AITL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Immunoblastic Lymphadenopathy / drug therapy. Immunoblastic Lymphadenopathy / therapy. Stem Cell Transplantation
  • [MeSH-minor] Aged. Carmustine / administration & dosage. Combined Modality Therapy. Cytarabine / administration & dosage. Disease Progression. Etoposide / administration & dosage. Female. Humans. Male. Melphalan / administration & dosage. Middle Aged. Neoplasm Recurrence, Local. Proportional Hazards Models. Remission Induction. Retrospective Studies. Survival Analysis. Transplantation Conditioning. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2009 Jul 1;27(19):3262
  • (PMID = 18182664.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine
  •  go-up   go-down


29. Rodriguez-Justo M, Attygalle AD, Munson P, Roncador G, Marafioti T, Piris MA: Angioimmunoblastic T-cell lymphoma with hyperplastic germinal centres: a neoplasia with origin in the outer zone of the germinal centre? Clinicopathological and immunohistochemical study of 10 cases with follicular T-cell markers. Mod Pathol; 2009 Jun;22(6):753-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma with hyperplastic germinal centres: a neoplasia with origin in the outer zone of the germinal centre? Clinicopathological and immunohistochemical study of 10 cases with follicular T-cell markers.
  • Angioimmunoblastic T-cell lymphoma is an aggressive peripheral T-cell lymphoma whose natural history is not fully understood.
  • The accurate recognition of Angioimmunoblastic T-cell lymphoma with pattern I remains a challenge and therefore the aim of this study is to phenotypically and morphologically characterize this variant with the use of the follicular helper T-cell (T(FH)) markers PD1, CXCL-13 and ICOS.
  • Out of the 88 Angioimmunoblastic T-cell lymphoma cases reviewed, 10 showed hyperplastic follicles.
  • Molecular probe methods for the detection of T-cell and B-cell clonality, as well as in-situ hybridization probes for EBV RNA expression, were carried out to leave no question as to the establishment of the diagnosis in each case.
  • By contrast, CD10 was found to only weakly label the neoplastic T cells, with only 5-10% of the target cell population staining for this marker.
  • Clinically, 8/9 cases presented with stage IIIB/IVB and in 2/10 cases consecutive biopsies showed 'progression' from pattern I to classical Angioimmunoblastic T-cell lymphoma.
  • In conclusion we have shown that the T(FH) cells markers PD1, CXCL13 and ICOS are useful adjuncts in the diagnosis of Angioimmunoblastic T-cell lymphoma with hyperplastic germinal centres.
  • PD1 also highlighted the presence of neoplastic cells in the outer zone of lymphoid follicles, suggesting that Angioimmunoblastic T-cell lymphoma (pattern I) may originate from T(FH) cells in this region, in accordance with previous immunological studies.
  • As the majority of cases in our series presented clinically with advanced stage disease, progression from pattern I to classical Angioimmunoblastic T-cell lymphoma may represent histological evolution rather than clinical progression.
  • [MeSH-major] Germinal Center / pathology. Lymph Nodes / pathology. Lymphoma, T-Cell / pathology. T-Lymphocytes, Helper-Inducer / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / metabolism. Antigens, Differentiation, T-Lymphocyte / metabolism. Apoptosis Regulatory Proteins / metabolism. Biomarkers, Tumor / immunology. Chemokine CXCL13 / metabolism. Female. Humans. Immunohistochemistry. Inducible T-Cell Co-Stimulator Protein. Male. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction. Programmed Cell Death 1 Receptor

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19329936.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Apoptosis Regulatory Proteins; 0 / Biomarkers, Tumor; 0 / Chemokine CXCL13; 0 / ICOS protein, human; 0 / Inducible T-Cell Co-Stimulator Protein; 0 / PDCD1 protein, human; 0 / Programmed Cell Death 1 Receptor
  •  go-up   go-down


30. Kyriakou C, Canals C, Finke J, Kobbe G, Harousseau JL, Kolb HJ, Novitzky N, Goldstone AH, Sureda A, Schmitz N: Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol; 2009 Aug 20;27(24):3951-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation.
  • PURPOSE: To analyze the long-term outcome in terms of nonrelapse mortality (NRM), relapse rate (RR), progression-free survival (PFS), and overall survival (OS) in patients with angioimmunoblastic T-cell lymphoma (AITL) treated with allogeneic stem-cell transplantation (alloSCT).
  • Median age was 48 years (range, 23 to 68 years), 34 patients had received > or = two lines of chemotherapy before alloSCT, and 11 patients had experienced treatment failure with a prior autologous stem-cell transplantation.
  • Twenty-seven patients were allografted in chemotherapy-sensitive disease, and 18 were allografted in refractory disease.
  • RR was estimated as 16% and 20% at 2 and 3 years, respectively, and was lower in patients developing chronic graft-versus-host disease (cGVHD).
  • Both the lower RR after transplantation as well as the decreased RR in patients developing cGVHD after the alloSCT suggests the existence of a clinically relevant graft-versus-lymphoma effect.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, T-Cell, Peripheral / therapy
  • [MeSH-minor] Adult. Aged. Female. Graft vs Host Disease / epidemiology. Humans. Male. Middle Aged. Recurrence. Retrospective Studies. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620487.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Bogdanos DP, Invernizzi P, Mackay IR, Vergani D: Autoimmune liver serology: current diagnostic and clinical challenges. World J Gastroenterol; 2008 Jun 7;14(21):3374-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Liver-related autoantibodies are crucial for the correct diagnosis and classification of autoimmune liver diseases (AiLD), namely autoimmune hepatitis types 1 and 2 (AIH-1 and 2), primary biliary cirrhosis (PBC), and the sclerosing cholangitis variants in adults and children.
  • AIH-2 is specified by antibody to liver kidney microsomal antigen type-1 (anti-LKM1) and anti-liver cytosol type 1 (anti-LC1).
  • SMA, ANA and anti-LKM antibodies can be present in de-novo AIH following liver transplantation.
  • PBC is specified by antimitochondrial antibodies (AMA) reacting with enzymes of the 2-oxo-acid dehydrogenase complexes (chiefly pyruvate dehydrogenase complex E2 subunit) and disease-specific ANA mainly reacting with nuclear pore gp210 and nuclear body sp100.
  • Sclerosing cholangitis presents as at least two variants, first the classical primary sclerosing cholangitis (PSC) mostly affecting adult men wherein the only (and non-specific) reactivity is an atypical perinuclear antineutrophil cytoplasmic antibody (p-ANCA), also termed perinuclear anti-neutrophil nuclear antibodies (p-ANNA) and second the childhood disease called autoimmune sclerosing cholangitis (ASC) with serological features resembling those of type 1 AIH.
  • [MeSH-major] Autoantibodies / blood. Autoantigens / immunology. Cholangitis, Sclerosing / diagnosis. Hepatitis, Autoimmune / diagnosis. Liver Cirrhosis, Biliary / diagnosis. Serologic Tests

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Immunol. 1969 May;4(5):511-25 [5787343.001]
  • [Cites] Immunology. 1969 Aug;17(2):281-93 [5804537.001]
  • [Cites] Am J Pathol. 1973 Sep;72(3):473-88 [4125700.001]
  • [Cites] Clin Exp Immunol. 1973 Nov;15(3):331-44 [4587503.001]
  • [Cites] Br Med J. 1974 Apr 13;2(5910):80-4 [4596402.001]
  • [Cites] Immunology. 1974 Mar;26(3):589-601 [4604207.001]
  • [Cites] Clin Exp Immunol. 1976 May;24(2):266-72 [945140.001]
  • [Cites] J Clin Pathol. 1976 May;29(5):403-10 [777046.001]
  • [Cites] Clin Exp Immunol. 1979 Dec;38(3):621-8 [93995.001]
  • [Cites] Clin Exp Immunol. 1983 Oct;54(1):232-8 [6352105.001]
  • [Cites] Clin Exp Immunol. 1984 Feb;55(2):347-54 [6199139.001]
  • [Cites] Lancet. 1984 Oct 27;2(8409):954-6 [6149344.001]
  • [Cites] Lancet. 1985 Feb 23;1(8426):425-9 [2857806.001]
  • [Cites] Lancet. 1987 Feb 7;1(8528):292-4 [2880112.001]
  • [Cites] J Immunol. 1987 May 15;138(10):3525-31 [3571977.001]
  • [Cites] Gastroenterol Clin Biol. 1987 Aug-Sep;11(8-9):614 [3653625.001]
  • [Cites] Hepatology. 1987 Nov-Dec;7(6):1333-9 [3679093.001]
  • [Cites] Liver. 1987 Dec;7(6):307-15 [3437792.001]
  • [Cites] Lancet. 1988 May 14;1(8594):1067-70 [2896910.001]
  • [Cites] J Exp Med. 1988 Aug 1;168(2):801-6 [2842431.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Nov;85(21):8256-60 [3186722.001]
  • [Cites] Hepatology. 2001 Mar;33(3):591-6 [11230739.001]
  • [Cites] J Hepatol. 2001 Mar;34(3):366-72 [11322196.001]
  • [Cites] Liver. 2001 Aug;21(4):225-32 [11454184.001]
  • [Cites] Hepatology. 2001 Sep;34(3):494-501 [11526534.001]
  • [Cites] Clin Exp Immunol. 2001 Oct;126(1):37-46 [11678897.001]
  • [Cites] Liver Int. 2006 Aug;26(6):633-5 [16842317.001]
  • [Cites] Clin Chim Acta. 2006 Nov;373(1-2):183-4; author reply 185 [16714006.001]
  • [Cites] Dig Liver Dis. 2006 Oct;38(10):781-2; author reply 782-3 [16870516.001]
  • [Cites] Hepatology. 2007 Jan;45(1):118-27 [17187436.001]
  • [Cites] J Clin Pathol. 2007 Jan;60(1):107-8 [17213359.001]
  • [Cites] Am J Gastroenterol. 2006 Dec;101(12):2731-6 [17227520.001]
  • [Cites] J Gastroenterol Hepatol. 2007 Mar;22(3):454-5 [17295788.001]
  • [Cites] Hepatology. 2007 Mar;45(3):659-65 [17326160.001]
  • [Cites] PLoS Biol. 2007 Jan;5(1):e4 [17194211.001]
  • [Cites] Diabetes Res Clin Pract. 2007 Jul;77(1):155-6 [17118481.001]
  • [Cites] Am J Gastroenterol. 2007 May;102(5):1131-2 [17489791.001]
  • [Cites] Semin Liver Dis. 2007 May;27(2):129-39 [17520513.001]
  • [Cites] Lancet. 1965 Oct 30;2(7418):878-9 [4158243.001]
  • [Cites] Gastroenterology. 1966 Oct;51(4):499-505 [5332194.001]
  • [Cites] J Exp Med. 1967 Aug 1;126(2):277-90 [4165742.001]
  • [Cites] Br J Exp Pathol. 1969 Apr;50(2):200-8 [5772074.001]
  • [Cites] J Autoimmun. 2004 Jun;22(4):353-62 [15120760.001]
  • [Cites] Semin Liver Dis. 2005 Aug;25(3):239-50 [16143941.001]
  • [Cites] Semin Liver Dis. 2005 Aug;25(3):298-310 [16143945.001]
  • [Cites] N Engl J Med. 2005 Sep 22;353(12):1261-73 [16177252.001]
  • [Cites] J Clin Pathol. 2006 Mar;59(3):280-4 [16505279.001]
  • [Cites] Hepatology. 2006 May;43(5):1135-44 [16628641.001]
  • [Cites] Semin Liver Dis. 2007 May;27(2):140-51 [17520514.001]
  • [Cites] Semin Liver Dis. 2007 May;27(2):161-72 [17520516.001]
  • [Cites] Hepatology. 2007 Jun;45(6):1583; author reply 1583-4 [17538935.001]
  • [Cites] J Clin Immunol. 2007 Jul;27(4):378-87 [17514501.001]
  • [Cites] J Clin Lab Anal. 2007;21(4):227-31 [17621358.001]
  • [Cites] Ann N Y Acad Sci. 2007 Aug;1109:519-30 [17785341.001]
  • [Cites] Liver Int. 2007 Nov;27(9):1226-31 [17919234.001]
  • [Cites] Hepatology. 1988 Nov-Dec;8(6):1662-6 [3192182.001]
  • [Cites] J Clin Invest. 1989 Mar;83(3):1066-72 [2466049.001]
  • [Cites] J Clin Invest. 1990 Jun;85(6):1967-73 [2347920.001]
  • [Cites] Hepatology. 1990 Jul;12(1):127-32 [2373473.001]
  • [Cites] Gastroenterology. 1992 Oct;103(4):1290-5 [1397887.001]
  • [Cites] Hepatology. 1992 Oct;16(4):892-8 [1398495.001]
  • [Cites] Hepatology. 1993 Mar;17(3):411-7 [8444414.001]
  • [Cites] J Immunol Methods. 1993 Feb 26;159(1-2):1-16 [8445241.001]
  • [Cites] Clin Exp Immunol. 1993 May;92(2):308-16 [7683589.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8454-9 [12832623.001]
  • [Cites] J Hepatol. 2003 Nov;39(5):860-3 [14568272.001]
  • [Cites] Hepatology. 2003 Nov;38(5):1250-7 [14578864.001]
  • [Cites] Clin Liver Dis. 2003 Nov;7(4):759-77, vi [14594130.001]
  • [Cites] Gastroenterology. 2003 Nov;125(5):1476-9 [14598264.001]
  • [Cites] J Hepatol. 2004 Jan;40(1):31-9 [14672611.001]
  • [Cites] Dig Liver Dis. 2003 Nov;35(11):801-5 [14674671.001]
  • [Cites] J Rheumatol. 2003 Nov;30(11):2374-81 [14677180.001]
  • [Cites] Clin Chem. 2004 Mar;50(3):682-3; author reply 683-4 [14981048.001]
  • [Cites] Int J Immunopathol Pharmacol. 2004 Jan-Apr;17(1):83-92 [15000871.001]
  • [Cites] Am J Gastroenterol. 2004 Apr;99(4):763-4; author reply 765 [15089915.001]
  • [Cites] Hepatology. 1997 Oct;26(4):1054-66 [9328334.001]
  • [Cites] Gastroenterology. 1998 Feb;114(2):324-8 [9453493.001]
  • [Cites] Lancet. 1998 Feb 7;351(9100):409-13 [9482295.001]
  • [Cites] Gut. 1998 May;42(5):721-6 [9659171.001]
  • [Cites] Hepatology. 1998 Aug;28(2):332-40 [9695994.001]
  • [Cites] Gastroenterology. 1999 Mar;116(3):643-9 [10029623.001]
  • [Cites] Ann Clin Biochem. 1999 Mar;36 ( Pt 2):189-95 [10370735.001]
  • [Cites] Experientia. 1954 Jun 15;10(6):252-3 [13183062.001]
  • [Cites] Proc Soc Exp Biol Med. 1954 Aug-Sep;86(4):789-94 [13204357.001]
  • [Cites] Lancet. 1956 Dec 29;271(6957):1323-6 [13386250.001]
  • [Cites] Hepatology. 2007 Nov;46(5):1436-42 [17657817.001]
  • [Cites] Autoimmunity. 2008 Feb;41(1):105-10 [18176872.001]
  • [Cites] Semin Liver Dis. 1997 Feb;17(1):71-8 [9089912.001]
  • [Cites] Semin Liver Dis. 1997 Feb;17(1):79-90 [9089913.001]
  • [Cites] Hepatology. 1997 May;25(5):1090-5 [9141422.001]
  • [Cites] J Hepatol. 1997 Jun;26(6):1396-402 [9210629.001]
  • [Cites] Hepatology. 1997 Sep;26(3):567-72 [9303484.001]
  • [Cites] Hepatology. 2008 Mar;47(3):1096-7; author reply 1097 [18306217.001]
  • [Cites] Proc Staff Meet Mayo Clin. 1948 Jan 21;23(2):25-8 [18921142.001]
  • [Cites] Hepatology. 1993 Jul;18(1):1-9 [8325600.001]
  • [Cites] J Hepatol. 1993 Aug;19(1):55-63 [8301043.001]
  • [Cites] J Clin Immunol. 1994 Jan;14(1):14-9 [8132733.001]
  • [Cites] Clin Exp Immunol. 1994 Jul;97(1):94-9 [8033426.001]
  • [Cites] Gastroenterology. 1995 Apr;108(4):1159-66 [7698584.001]
  • [Cites] Biochem Mol Biol Int. 1995 Mar;35(3):473-85 [7773184.001]
  • [Cites] Gut. 1995 May;36(5):749-54 [7797126.001]
  • [Cites] Gut. 1995 Sep;37(3):406-12 [7590439.001]
  • [Cites] J Immunol Methods. 1995 Dec 1;187(2):259-64 [7499885.001]
  • [Cites] Hepatology. 1996 Jul;24(1):97-103 [8707289.001]
  • [Cites] Dig Dis Sci. 1996 Sep;41(9):1733-40 [8794787.001]
  • [Cites] Hepatology. 1996 Nov;24(5):1068-73 [8903377.001]
  • [Cites] Hepatology. 1997 Jan;25(1):6-11 [8985257.001]
  • [Cites] Hepatology. 1997 Mar;25(3):541-7 [9049195.001]
  • [Cites] Semin Liver Dis. 1997 Feb;17(1):61-9 [9089911.001]
  • [Cites] J Hepatol. 1999 Oct;31(4):635-40 [10551386.001]
  • [Cites] J Hepatol. 1999 Nov;31(5):929-38 [10580593.001]
  • [Cites] Am J Gastroenterol. 2001 Dec;96(12):3447-8 [11774973.001]
  • [Cites] J Hepatol. 2002 Jan;36(1):14-21 [11804659.001]
  • [Cites] J Rheumatol. 2002 Jan;29(1):68-74 [11824974.001]
  • [Cites] Hepatology. 2002 Mar;35(3):658-64 [11870381.001]
  • [Cites] J Clin Lab Anal. 2002;16(4):194-201 [12112392.001]
  • [Cites] Gut. 2002 Aug;51(2):259-64 [12117891.001]
  • [Cites] J Clin Pathol. 2002 Dec;55(12):906-9 [12461054.001]
  • [Cites] J Immunol. 2003 Feb 1;170(3):1481-9 [12538711.001]
  • [Cites] Am J Gastroenterol. 2003 Feb;98(2):241-3 [12591035.001]
  • [Cites] Am J Gastroenterol. 2003 Feb;98(2):431-7 [12591064.001]
  • [Cites] Clin Chem. 2003 Apr;49(4):634-43 [12651817.001]
  • [Cites] J Autoimmun. 2003 May;20(3):247-54 [12753810.001]
  • [Cites] Autoimmunity. 2002 Dec;35(8):475-83 [12765472.001]
  • [Cites] Autoimmunity. 2002 Dec;35(8):485-92 [12765473.001]
  • [Cites] Autoimmunity. 2002 Dec;35(8):515-9 [12765477.001]
  • [Cites] Autoimmunity. 2002 Dec;35(8):545-50 [12765481.001]
  • [Cites] Arthritis Res Ther. 2003;5(4):192-201 [12823850.001]
  • [Cites] N Engl J Med. 1958 Jan 23;258(4):185-8 [13493762.001]
  • [Cites] Proc Soc Exp Biol Med. 1957 Dec;96(3):575-9 [13505796.001]
  • [Cites] Lancet. 1959 Jan 10;1(7063):65-9 [13621639.001]
  • [Cites] Cancer Res. 1955 Oct;15(9):598-602 [13261081.001]
  • [Cites] J Clin Invest. 1959 Nov;38:2059-72 [14402750.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Dec;2(12):1116-22 [15625657.001]
  • [Cites] Clin Infect Dis. 2005 Feb 15;40(4):508-10 [15712071.001]
  • [Cites] Hepatology. 2005 Mar;41(3):609-16 [15726652.001]
  • [Cites] Hepatology. 2005 Aug;42(2):458-65 [16025495.001]
  • [Cites] Scand J Gastroenterol. 2004 Apr;39(4):405-6; author reply 407 [15125479.001]
  • [Cites] Clin Infect Dis. 2004 May 15;38(10):1505; author reply 1505-6 [15156495.001]
  • [Cites] J Hepatol. 2004 Jul;41(1):31-7 [15246204.001]
  • [Cites] J Hepatol. 2004 Oct;41(4):677-83 [15464251.001]
  • [Cites] Scand J Gastroenterol. 2004 Oct;39(10):981-7 [15513338.001]
  • [Cites] N Engl J Med. 2000 Apr 27;342(17):1266-71 [10781624.001]
  • [Cites] Lancet. 2000 Apr 29;355(9214):1510-5 [10801173.001]
  • [Cites] Gastroenterology. 2000 Aug;119(2):310-22 [10930366.001]
  • [Cites] Dig Liver Dis. 2000 Jun-Jul;32(5):440-6 [11030191.001]
  • [Cites] Am J Gastroenterol. 2000 Nov;95(11):3238-41 [11095348.001]
  • [Cites] Gastroenterology. 2001 Jan;120(1):239-49 [11208733.001]
  • [Cites] Hepatology. 2001 Mar;33(3):544-53 [11230733.001]
  • (PMID = 18528935.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Autoantigens; 0 / Reagent Kits, Diagnostic
  • [Number-of-references] 154
  • [Other-IDs] NLM/ PMC2716592
  •  go-up   go-down


32. Tomita N, Motomura S, Hyo R, Takasaki H, Takemura S, Taguchi J, Fujisawa S, Ogawa K, Ishigatsubo Y, Takeuchi K: Comparison of peripheral T-cell lymphomas and diffuse large B-cell lymphoma. Cancer; 2007 Mar 15;109(6):1146-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of peripheral T-cell lymphomas and diffuse large B-cell lymphoma.
  • BACKGROUND: Peripheral T-cell lymphomas (PTCLs) are a biologically heterogeneous subgroup of lymphomas with poor prognosis.
  • In this study, the authors analyzed the clinical behaviors of PTCLs and diffuse large B-cell lymphoma (DLBCL).
  • METHODS: The authors compared the characteristics and outcomes of 59 patients with PTCLs, including 33 angioimmunoblastic T-cell lymphomas and 26 unspecified peripheral T-cell lymphomas, with the characteristics and outcomes of 193 patients with DLBCLs who were treated in the era before rituximab.
  • The 5-year overall survival (OS), progression-free survival (PFS), and disease-free survival (DFS) rates were 31%, 26%, and 47%, respectively, in patients with PTCLs and 59%, 55%, and 73%, respectively, in patients with DLBCL (P = .001, P < .001, and P = .003, respectively).
  • T-cell phenotype itself did not appear to have a significant impact on either response or survival.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / mortality. Lymphoma, T-Cell, Peripheral / diagnosis. Lymphoma, T-Cell, Peripheral / mortality


33. Kojima M, Motoori T, Matsuda H, Iijima M, Masawa N, Nakamura S: Atypical lymphoplasmacytic and immunoblastic proliferation from systemic lupus erythematosus. A case report. Pathol Res Pract; 2005;201(7):531-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical lymphoplasmacytic and immunoblastic proliferation from systemic lupus erythematosus. A case report.
  • A case of atypical lymphoplasmacytic and immunoblastic proliferation (ALPIBP) in the lymph nodes associated with well-documented systemic lupus erythematosus (SLE) is presented.
  • A 30-year-old Japanese female with an 18-year history of SLE presented with right neck lymphadenopathy of 3 months duration.
  • Interestingly, the immunohistochemical study demonstrated large, irregularly shaped accumulations of follicular dendritic cells (FDCs) surrounding the small vessels, which is an immunohistochemical finding characteristic of angioimmunoblastic T-cell lymphoma (AILT).
  • However, the present lesion showed the following differences to AILT: (a) absence of CD3+, CD4+ and CD10+ clear cells, which are tumor cells of AILT;.
  • (c) on molecular analysis, the present case demonstrated a polyclonal pattern converse to the monoclonal T-cell receptor gamma chain gene rearrangement in most AILTs (d) absence of EBV infected lymphoid cells, which are frequently detected AILT.
  • As previously suggested, the present case indicates that a clinical correlation as well as immunohistologic and genotypic studies may be necessary to discriminate between ALPIBPs and AILT.
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Immunoblastic Lymphadenopathy / pathology. Immunohistochemistry

  • Genetic Alliance. consumer health - Lupus.
  • Genetic Alliance. consumer health - Systemic lupus erythematosus.
  • MedlinePlus Health Information. consumer health - Lupus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16164050.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


34. Win N, Tiwari D, Keevil VL, Needs M, Lakhani A: Mixed-type autoimmune haemolytic anaemia: unusual cases and a case associated with splenic T-cell angioimmunoblastic non-Hodgkin's lymphoma. Hematology; 2007 Apr;12(2):159-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed-type autoimmune haemolytic anaemia: unusual cases and a case associated with splenic T-cell angioimmunoblastic non-Hodgkin's lymphoma.
  • The diagnosis of mixed-type autoimmune haemolytic anaemia (AIHA) is based on demonstrating the presence of "warm" IgG auto-antibody and "low titre" ( < 64 at 4 degrees C), "high thermal amplitude" (reacting at or >30 degrees C) "cold" IgM auto-antibody.
  • Mixed-type AIHA is uncommon.
  • Red cell agglutination on the peripheral blood film is a common finding in mixed-type AIHA and can lead, initially, to a mis-diagnosis of cold haemmagglutinin disease (CHAD).
  • Mixed-type AIHA is rare and can be idiopathic or secondary, often associated with systemic lupus erythematosus (SLE) and lymphoma.
  • In general, patients with mixed-type AIHA show a dramatic response to steroid therapy and frequently require few or no transfusions.
  • We report two unusual cases of mixed-type AIHA.
  • Case two, we believe, is the first reported case of splenic T cell angioimmunoblastic non-Hodgkins lymphoma (NHL) associated with mixed-type AIHA.
  • DAT tested with monospecific reagents, and thorough serological investigations is required to reach the diagnosis of mixed-type AIHA.
  • [MeSH-major] Anemia, Hemolytic, Autoimmune / etiology. Anti-Inflammatory Agents / adverse effects. Lymphoma, T-Cell / complications. Paraneoplastic Syndromes / etiology. Prednisolone / adverse effects. Splenic Neoplasms / complications
  • [MeSH-minor] Aged. Antibodies, Anti-Idiotypic / blood. Antibodies, Anti-Idiotypic / immunology. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Autoantibodies / blood. Autoantibodies / immunology. Combined Modality Therapy. Complement C3d / immunology. Coombs Test. Cryoglobulins / analysis. Cryoglobulins / immunology. Cyclophosphamide / administration & dosage. Diagnosis, Differential. Erythrocyte Transfusion. Fatal Outcome. Female. Humans. Immunoglobulin G / blood. Immunoglobulin G / immunology. Immunoglobulin M / blood. Immunoglobulin M / immunology. Immunoglobulins, Intravenous / therapeutic use. Immunosuppressive Agents / therapeutic use. Immunotherapy. Male. Osteoarthritis / drug therapy. Prednisone / administration & dosage. Rituximab. Splenectomy. Temperature. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17454198.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antibodies, Anti-Idiotypic; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Autoantibodies; 0 / Cryoglobulins; 0 / Immunoglobulin G; 0 / Immunoglobulin M; 0 / Immunoglobulins, Intravenous; 0 / Immunosuppressive Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80295-45-0 / Complement C3d; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VB0R961HZT / Prednisone; COP protocol 2
  •  go-up   go-down


35. Yuan CM, Vergilio JA, Zhao XF, Smith TK, Harris NL, Bagg A: CD10 and BCL6 expression in the diagnosis of angioimmunoblastic T-cell lymphoma: utility of detecting CD10+ T cells by flow cytometry. Hum Pathol; 2005 Jul;36(7):784-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD10 and BCL6 expression in the diagnosis of angioimmunoblastic T-cell lymphoma: utility of detecting CD10+ T cells by flow cytometry.
  • Angioimmunoblastic T-cell lymphoma (AITCL) is a histologically distinct and relatively common subtype of T-cell lymphoma.
  • Although the putative normal cell counterpart is a mature CD4+ T cell, the precise cell of origin remains elusive.
  • We evaluated cases with a diagnosis of AITCL to determine the specificity and utility of CD10 coexpression, particularly by flow cytometry (FCM), in facilitating this diagnosis.
  • Four cases of peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), were also analyzed.
  • The lymphoma cells in all 8 AITCL cases were CD4+, CD45RO+ T cells, with classic extrafollicular meshworks of CD21/CD23/CD35+ follicular dendritic cells.
  • CD10 coexpression was not observed in all 4 PTCL-NOS cases.
  • Although not specific for AITCL, increased numbers of BCL6+ cells were seen in AITCL as compared with PTCL-NOS.
  • The finding suggests that AITCL may be a neoplasm of (possibly intrafollicular) CD10+, BCL6+, and CD4+ memory T cells.
  • Although our series is small, our results suggest that CD10 coexpression may be a useful discriminant, particularly if the differential diagnosis is PTCL-NOS, and demonstrate that this can be determined by FCM.
  • [MeSH-major] DNA-Binding Proteins / metabolism. Flow Cytometry. Immunoblastic Lymphadenopathy / metabolism. Lymphoma, T-Cell / metabolism. Neprilysin / metabolism. T-Lymphocytes / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] Antigens, CD45 / metabolism. CD4-Positive T-Lymphocytes / metabolism. CD4-Positive T-Lymphocytes / pathology. Cell Count. Diagnosis, Differential. Humans. Immunoenzyme Techniques. Lymphoma, T-Cell, Peripheral / metabolism. Lymphoma, T-Cell, Peripheral / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16084948.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; 0 / Transcription Factors; EC 3.1.3.48 / Antigens, CD45; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


36. Windsor R, Stiller C, Webb D: Peripheral T-cell lymphoma in childhood: population-based experience in the United Kingdom over 20 years. Pediatr Blood Cancer; 2008 Apr;50(4):784-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T-cell lymphoma in childhood: population-based experience in the United Kingdom over 20 years.
  • BACKGROUND: Peripheral T-cell lymphomas (PTCL) are very rare in children and this has prevented assessment of best treatment and prognosis.
  • Anaplastic large cell lymphoma and mycosis fungoides were excluded due to recent publications describing UK experience with these disorders.
  • RESULTS: Twenty-five cases were identified, comprising 1.6% of non-Hodgkin lymphoma (NHL) registrations; 17 (68%) children with PTCL-unspecified (PTCL-u), 3 (12%) with angiocentric PTCL, 3 (12%) with angioimmunoblastic PTCL, and 2 (8%) with subcutaneous panniculitis-like T-cell lymphoma.
  • Eighteen children were male, with a male/female ratio of 2.6:1.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell, Peripheral / drug therapy

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18022899.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


37. Warnke RA, Jones D, Hsi ED: Morphologic and immunophenotypic variants of nodal T-cell lymphomas and T-cell lymphoma mimics. Am J Clin Pathol; 2007 Apr;127(4):511-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphologic and immunophenotypic variants of nodal T-cell lymphomas and T-cell lymphoma mimics.
  • Given their relative rarity, one of the primary diagnostic difficulties in nodal T-cell lymphomas is recognizing their range of histologic patterns.
  • This is complicated by the fact that most mature T-cell lymphomas retain some functional characteristics of nonneoplastic T cells, ie, the capacity to secrete cytokines and costimulate immune cell growth, and, thus, are associated with obscuring nonneoplastic immune cells.
  • Sessions 2 and 3 of the Society for Hematopathology/European Association for Haematopathology Workshop focused on these issues and conditions that may simulate T-cell lymphomas.
  • We summarize salient features of presented cases, including the varied patterns seen in angioimmunoblastic T-cell lymphoma (AITL) and other more poorly characterized morphologic and functional nodal T-cell lymphoma subsets.
  • Many cases illustrated the difficulties distinguishing AITL from peripheral T-cell lymphoma, unspecified, when the neoplasms manifest only some AITL features.
  • The usefulness of separately classifying T-cell lymphomas that demonstrate follicular, perifollicular, or T-zone patterns of infiltration; significance of immunophenotypically distinct subsets that express cytotoxic markers or have features of central memory T cells; diagnostic difficulties posed by B-cell proliferations that accompany T-cell lymphomas; and T-cell lymphoma mimics related to genetic disorders, immune dysregulation, and drug reactions are also discussed.
  • [MeSH-major] Biomarkers, Tumor / analysis. Lymph Nodes / pathology. Lymphoma, T-Cell / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunophenotyping

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17369127.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Congresses
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


38. Murakami YI, Yatabe Y, Sakaguchi T, Sasaki E, Yamashita Y, Morito N, Yoh K, Fujioka Y, Matsuno F, Hata H, Mitsuya H, Imagawa S, Suzuki A, Esumi H, Sakai M, Takahashi S, Mori N: c-Maf expression in angioimmunoblastic T-cell lymphoma. Am J Surg Pathol; 2007 Nov;31(11):1695-702
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] c-Maf expression in angioimmunoblastic T-cell lymphoma.
  • We previously examined c-Maf expression in various T-cell lymphomas by reverse-transcription polymerase chain reaction and found extremely elevated c-Maf levels in angioimmunoblastic T-cell lymphoma (AILT).
  • In this study, we examined T-cell lymphomas for c-Maf and cyclin expression immunohistochemically.
  • Of 93 cases of T-cell lymphomas we investigated in the current study, c-Maf expression was seen in 23 out of 31 cases of AILT, 3 out of 11 of adult T-cell leukemia/lymphoma, 4 out of 19 of peripheral T-cell lymphoma, unspecified [PTCL(U)], and 0 out of 11 cases of mycosis fungoides, 0 out of 11 of anaplastic large cell lymphoma, and 1 out of 10 of extranodal NK/T-cell lymphoma, nasal type.
  • Double immunostaining in AILT revealed that the majority of c-Maf-positive cells were also positive for CD43 (MT1), CD45RO (UCHL-1), and CD4 but were negative for CD20 (L26).
  • Additionally, cyclins D1 and D2, which stimulate cell cycle progression, were overexpressed in a large number of the c-Maf-positive AILT samples.
  • Quantitative reverse-transcription polymerase chain reaction analysis also showed that c-Maf was overexpressed in 8/31 cases of AILT, 0/19 cases of PTCL(U), 0/11 cases of anaplastic large cell lymphoma, 0/10 cases of extranodal NK/T-cell lymphoma, nasal type, and 2/8 cases of multiple myeloma, presenting significant difference between AILT and PTCL(U) (P=0.016, chi test).
  • These findings strongly suggest that CD4-positive neoplastic T cells in AILT show c-Maf expression and provide new insight into the pathogenesis of AILT suggesting c-Maf to be a useful diagnostic marker for AILT.
  • [MeSH-major] Biomarkers, Tumor / analysis. Immunoblastic Lymphadenopathy / metabolism. Lymphoma, T-Cell / chemistry. Proto-Oncogene Proteins c-maf / analysis

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18059226.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD4; 0 / Antigens, CD43; 0 / Biomarkers, Tumor; 0 / CCND2 protein, human; 0 / Cyclin D; 0 / Cyclin D2; 0 / Cyclins; 0 / MAF protein, human; 0 / Proto-Oncogene Proteins c-maf; 0 / RNA, Messenger; 0 / UN1 sialoglycoprotein, human; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


39. Miyazaki K, Masuya M, Yamaguchi M, Isaka S, Nakase K, Kobayashi T, Nakamura S, Shiku H: [Angioimmunoblastic T-cell lymphoma occurring four months after autologous peripheral blood stem cell transplantation with high-dose chemotherapy for follicular lymphoma]. Rinsho Ketsueki; 2005 Sep;46(9):1065-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angioimmunoblastic T-cell lymphoma occurring four months after autologous peripheral blood stem cell transplantation with high-dose chemotherapy for follicular lymphoma].
  • A 62-year-old Japanese woman was diagnosed as having follicular lymphoma (FL, grade 3, CS IIIA, IPI high-intermediate risk) in May 1998.
  • High-dose etoposide was used for autologous peripheral stem cell mobilization.
  • In May 1999, she underwent high-dose chemotherapy with autologous peripheral blood stem cell transplantation (auto-PBSCT).
  • Four months after the auto-PBSCT, bilateral cervical lymphadenopathy developed.
  • Histopathological findings from a biopsied cervical lymph node showed angioimmunoblastic T-cell lymphoma (AILT).
  • The patient was treated with modified CVP therapy, and she is alive with no evidence of lymphoma five years after auto-PBSCT.
  • Clinical and histopathological findings showed that the FL and AILT in this case were not concomitant.
  • It is thought that in this case, the AILT developed as a post-transplant lymphoproliferative disorder after auto-PBSCT for the FL.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / adverse effects. Etoposide / adverse effects. Immunoblastic Lymphadenopathy / etiology. Lymphoma, Follicular / therapy. Lymphoma, T-Cell / etiology. Peripheral Blood Stem Cell Transplantation / adverse effects


40. Xie JL, Zhou XG: Infectious mononucleosis-like lesions, a rare manifestation of angioimmunoblastic T-cell lymphoma. Leuk Lymphoma; 2010 May;51(5):944-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infectious mononucleosis-like lesions, a rare manifestation of angioimmunoblastic T-cell lymphoma.
  • [MeSH-major] Epstein-Barr Virus Infections / diagnosis. Immunoblastic Lymphadenopathy / diagnosis. Infectious Mononucleosis / diagnosis. Lymphoma, T-Cell / diagnosis

  • MedlinePlus Health Information. consumer health - Infectious Mononucleosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20350275.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


41. Chang ST, Lu CL, Chuang SS: CD52 expression in non-mycotic T- and NK/T-cell lymphomas. Leuk Lymphoma; 2007 Jan;48(1):117-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD52 expression in non-mycotic T- and NK/T-cell lymphomas.
  • Campath-1H or alemtuzumab, a human anti-CD52, has been shown to be effective in T-cell malignancies; however, there is very limited information on CD52 expression in T-cell lymphoma (TCL).
  • Fourteen cases of angioimmunoblastic T-cell lymphoma (AITL) were excluded as there were no reliable criteria to differentiate whether the CD52-positive cells were neoplastic T-cells, which are usually small-sized, or the usually abundant, small-to-large residual/reactive B-cells in this lymphoma sub-type.
  • In the remaining 83 tumors, CD52 was expressed in 29 (35%) tumors including 8/17 (47%) NK/T-cell lymphomas, 14/35 (40%) unspecified peripheral TCLs and 4/18 (22%) anaplastic large cell lymphomas.
  • [MeSH-major] Antigens, CD / metabolism. Antigens, Neoplasm / metabolism. Glycoproteins / metabolism. Lymphoma, T-Cell / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17325855.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / CD52 antigen; 0 / Glycoproteins
  •  go-up   go-down


42. Reimer P, Rüdiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N, Engert A, Einsele H, Müller-Hermelink HK, Wilhelm M: Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol; 2009 Jan 1;27(1):106-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study.
  • PURPOSE: Peripheral T-cell lymphomas (PTCLs) are rare malignancies with poor outcome after conventional chemotherapy.
  • The role of myeloablative therapy and autologous stem-cell transplantation (autoSCT) is still unclear.
  • PATIENTS AND METHODS: The treatment regimen consisted of four to six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone followed by mobilizing therapy with either the dexamethasone, carmustine, melphalan, etoposide, and cytarabine protocol or the etoposide, methylprednisolone, cytarabine, and cisplatin protocol and stem-cell collection.
  • Main subgroups were PTCL not specified (n = 32) and angioimmunoblastic T-cell lymphoma (n = 27).
  • The main reason for not receiving autoSCT was progressive disease.
  • With a median follow-up time of 33 months, 43 patients are alive; the estimated 3-year overall and disease-free survival rates for patients in CR (calculated from CR to the date of relapse) and 3-year progression-free survival rate were 48%, 53%, and 36%, respectively.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, T-Cell, Peripheral / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Expert Rev Hematol. 2009 Jun;2(3):255-60 [21082967.001]
  • (PMID = 19029417.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / CD52 antigen; 0 / Glycoproteins
  •  go-up   go-down


43. Yamamoto H, Miwa H, Kato Y, Nakamura S, Hara K, Nitta M: Angioimmunoblastic T cell lymphoma with an unusual proliferation of Epstein-Barr virus-associated large B cells arising in a patient with progressive systemic sclerosis. Acta Haematol; 2005;114(2):108-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T cell lymphoma with an unusual proliferation of Epstein-Barr virus-associated large B cells arising in a patient with progressive systemic sclerosis.
  • We report an unusual case of angioimmunoblastic T cell lymphoma arising in the setting of 5 years of immunosuppressive treatment for progressive systemic sclerosis.
  • Southern blot study demonstrated the clonal rearrangement of T cell receptor beta-chain gene, but not of immunoglobulin heavy chain gene.
  • Phenotypical examination of the lymph node also revealed the predominance of CD4+ T cells in addition to the proliferation of follicular dendritic cells, but no light chain restriction in large B cell components.
  • Based on the combined data described here, our preferred diagnosis was angioimmunoblastic T cell lymphoma with Epstein-Barr virus-associated B cell lymphoproliferative disorder, the pathogenesis of which was suggested to be closely associated with immunosuppressive treatment for progressive systemic sclerosis.
  • [MeSH-major] Epstein-Barr Virus Infections / pathology. Herpesvirus 4, Human. Lymphoma, B-Cell / pathology. Lymphoma, T-Cell / pathology. Scleroderma, Diffuse / pathology

  • Genetic Alliance. consumer health - Diffuse Scleroderma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 16103635.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


44. Zhang D, Saunders CJ, Zhao W, Davis M, Cunningham MT: The clonality of CD3+ CD10+ T cells in angioimmunoblastic T cell lymphoma, B cell lymphoma, and reactive lymphoid hyperplasia. Am J Hematol; 2009 Sep;84(9):606-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clonality of CD3+ CD10+ T cells in angioimmunoblastic T cell lymphoma, B cell lymphoma, and reactive lymphoid hyperplasia.
  • T cells coexpressing CD3 and CD10 are a characteristic feature of angioimmunoblastic T-cell lymphoma (AITL) [1].
  • However, they are not unique to AITL, as these cells are also present in B cell lymphoma and reactive lymphoid hyperplasia [2].
  • To determine the significance of CD3+ CD10+ T cells, we used flow cytometry with cell sorting and molecular biology techniques for T cell gene rearrangement to study T cells from patients with AITL, B cell lymphoma, and reactive lymph node hyperplasia.
  • We found that CD3+ CD10+ T cells in B cell lymphoma and reactive lymphoid hyperplasia were polyclonal.
  • These findings illustrate the differences between early and late lymphoma and could be important for the diagnosis of AITL.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, T-Cell / pathology. Pseudolymphoma / pathology. T-Lymphocytes / pathology
  • [MeSH-minor] Clone Cells. Humans. Immunoblastic Lymphadenopathy / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19650143.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  •  go-up   go-down


45. Ren YL, Hong L, Nong L, Zhang S, Li T: [Clinicopathologic, immunohistochemical and molecular analysis in 15 cases of angioimmunoblastic T-cell lymphomas]. Beijing Da Xue Xue Bao; 2008 Aug 18;40(4):352-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic, immunohistochemical and molecular analysis in 15 cases of angioimmunoblastic T-cell lymphomas].
  • OBJECTIVE: To evaluate angioimmunoblastic T-cell lymphoma(AITL) completely, we gave injdepth investigation of histopathological features, specific immunochemical markers, antigen receptor gene rearrangements and in situ hybridization for Epstein-Barr virus (EBV).
  • Polymerase chain reaction for immunoglobulin heavy chain (IgH) and T cell receptor gamma (TCRgamma) rearrangements and in situ hybridization for Epstein-Barr virus encoded RNA (EBER-1) were performed.
  • CD21 expression exihibited extrafollicular expansion of follicular dendritic cell meshworks in 11 cases (73.3%), partially with a tendency of perivascular distribution.
  • Among the four cases with large B cell proliferation, three were EBV-positive.
  • Only when we recognize such diversity, can we reasonably apply and properly evaluate immunochemical markers and molecular techniques, and thus give a correct diagnosis.
  • [MeSH-major] Gene Rearrangement, T-Lymphocyte. Immunoblastic Lymphadenopathy. Lymphoma, T-Cell, Peripheral
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Epstein-Barr Virus Infections / metabolism. Epstein-Barr Virus Infections / pathology. Female. Humans. Immunoglobulin Heavy Chains / genetics. Immunohistochemistry. Male. Middle Aged. Receptors, Antigen, T-Cell, gamma-delta / genetics. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18677379.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Receptors, Antigen, T-Cell, gamma-delta
  •  go-up   go-down


46. Moulin C, Debarbieux S, Ducastelle-Lepretre S, Fabien N, Depaepe L, Veysseyre-Balter C, Fremeaux-Bacchi V, Isaac S, Balme B, Thomas L: Urticarial vasculitis and asymptomatic acquired C1 esterase inhibitor deficiency revealing an angioimmunoblastic T cell lymphoma. Eur J Dermatol; 2010 Jul-Aug;20(4):515-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urticarial vasculitis and asymptomatic acquired C1 esterase inhibitor deficiency revealing an angioimmunoblastic T cell lymphoma.
  • [MeSH-major] Hereditary Angioedema Types I and II / diagnosis. Immunoblastic Lymphadenopathy / diagnosis. Lymphoma, T-Cell, Peripheral / diagnosis. Vasculitis / diagnosis
  • [MeSH-minor] Complement C1 Inhibitor Protein / metabolism. Diagnosis, Differential. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Vasculitis.
  • MedlinePlus Health Information. consumer health - Vasculitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20507835.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Complement C1 Inhibitor Protein
  •  go-up   go-down


47. Nelson M, Horsman DE, Weisenburger DD, Gascoyne RD, Dave BJ, Loberiza FR, Ludkovski O, Savage KJ, Armitage JO, Sanger WG: Cytogenetic abnormalities and clinical correlations in peripheral T-cell lymphoma. Br J Haematol; 2008 May;141(4):461-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic abnormalities and clinical correlations in peripheral T-cell lymphoma.
  • Cytogenetic correlations among most types of peripheral T-cell lymphoma (PTCL) have not been very informative to date.
  • This study aimed to identify recurrent chromosomal abnormalities in angioimmunoblastic T-cell lymphoma (AITL), ALK-negative anaplastic large cell lymphoma (ALK-ALCL) and peripheral T-cell lymphoma, unspecified (PTCL-US), and to evaluate their prognostic value.
  • [MeSH-major] Chromosome Aberrations. Lymphoma, T-Cell, Peripheral / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Follow-Up Studies. Humans. Immunoblastic Lymphadenopathy / genetics. Karyotyping. Lymphoma, Large-Cell, Anaplastic / genetics. Male. Middle Aged. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18341637.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


48. Tajika K, Tamai H, Mizuki T, Nakayama K, Yamaguchi H, Dan K: [Epstein-Barr virus-related B-cell lymphoma of the skin which developed early after cord blood transplantation for angioimmunoblastic T-cell lymphoma]. Rinsho Ketsueki; 2010 Feb;51(2):138-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epstein-Barr virus-related B-cell lymphoma of the skin which developed early after cord blood transplantation for angioimmunoblastic T-cell lymphoma].
  • We report here a rare case of EBV-related post-transplantation lymphoproliferative disorder (PTLD) localized to the skin.
  • The patient was a 64-year-old man diagnosed with angioimmunoblastic T cell lymphoma (AITL).
  • He underwent cord blood transplantation with a reduced intensity conditioning regimen during partial remission after chemotherapy.
  • Chimerism analysis revealed that the tumor cells were derived from donor cells, which led to the diagnosis of EBV-related PTLD.
  • [MeSH-major] Fetal Blood / transplantation. Herpesvirus 4, Human. Immunoblastic Lymphadenopathy / therapy. Lymphoma, T-Cell / therapy. Lymphoproliferative Disorders / virology. Skin Diseases / virology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20379106.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


49. Schmitz N, Trümper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, Peter N, Loeffler M, Rosenwald A, Pfreundschuh M: Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood; 2010 Nov 4;116(18):3418-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.
  • To evaluate outcome and prognosis of patients with T-cell lymphoma we analyzed 343 patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).
  • Two hundred eighty-nine patients belonged to 1 of the 4 major T-cell lymphoma subtypes: anaplastic large cell lymphoma (ALCL), anaplastic large cell lymphoma kinase (ALK)-positive (n = 78); ALCL, ALK-negative (n = 113); peripheral T-cell lymphoma, unspecified (PTCLU; n = 70); and angioimmunoblastic T-cell lymphoma (AITL; n = 28).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cohort Studies. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Female. Humans. Killer Cells, Natural / pathology. Lymphoma, Extranodal NK-T-Cell / diagnosis. Lymphoma, Extranodal NK-T-Cell / drug therapy. Lymphoma, Extranodal NK-T-Cell / pathology. Male. Middle Aged. Prednisone / administration & dosage. Prednisone / therapeutic use. Prognosis. Treatment Outcome. Vincristine / administration & dosage. Vincristine / therapeutic use. Young Adult


50. Rüdiger T, Geissinger E, Müller-Hermelink HK: 'Normal counterparts' of nodal peripheral T-cell lymphoma. Hematol Oncol; 2006 Dec;24(4):175-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 'Normal counterparts' of nodal peripheral T-cell lymphoma.
  • Peripheral T-cell lymphomas (PTCL) have been difficult to classify.
  • A homogeneous principle of classification is still lacking, partly because lymph node compartments containing functionally distinct T-cell subsets have not been identified.
  • A correlation to differentiated T-cell subsets, as CD4(+) or CD8(+) cells as well as cytotoxic populations has not revealed clinically meaningful entities.
  • Immunohistological analysis of PTCL showed an effector or effector-memory cell phenotype (CD45RA(-)/CD45R0(+)/CD27(-)) for both angioimmunoblastic T-cell lymphoma (AILT) and anaplastic large cell lymphoma (ALCL), but different cytotoxic and activation markers expressed by these tumours.
  • A subset of CD4(+) PTCL-not otherwise specified (PTCL-NOS) may correspond to a central memory cell phenotype (CD45RA(-)/CD45R0(+)/CD27(+)).
  • A comparison between the lymphomas and their normal counterparts may contribute to the understanding of the underlying transformation mechanisms.
  • [MeSH-major] Antigens, Differentiation, T-Lymphocyte / immunology. CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Cell Differentiation / immunology. Immunologic Memory. Lymphoma, T-Cell, Peripheral / immunology
  • [MeSH-minor] Cell Transformation, Neoplastic / immunology. Gene Expression Regulation, Leukemic / immunology. Humans. Lymph Nodes / immunology. Lymph Nodes / pathology. Lymphocyte Activation / immunology. Lymphoma, Large B-Cell, Diffuse / classification. Lymphoma, Large B-Cell, Diffuse / immunology. Lymphoma, Large B-Cell, Diffuse / pathology

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16783841.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Differentiation, T-Lymphocyte
  • [Number-of-references] 73
  •  go-up   go-down


51. Jiang L, Yuan CM, Hubacheck J, Janik JE, Wilson W, Morris JC, Jasper GA, Stetler-Stevenson M: Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy. Br J Haematol; 2009 Apr;145(2):173-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy.
  • The anti-CD52 antibody alemtuzumab has been explored as a novel targeted therapy in T cell malignancies.
  • To assess the suitability of alemtuzumab therapy, we carried out a comprehensive study of CD52 expression using flow cytometry (FC) in 78 untreated patients diagnosed with mature T/natural killer (NK) cell neoplasms, including 34 adult T cell leukaemia/lymphomas (ATLL), two anaplastic large cell lymphomas (ALCL), three angioimmunoblastic T cell lymphomas (AITL), 16 cutaneous T cell lymphomas (CTCL), four extra-nodal T/NK cell lymphomas (ENT/NKCL), four hepatosplenic T cell lymphomas (HSTCL), 13 peripheral T cell lymphomas, not otherwise specified (PTCL-NOS) and two T-prolymphocytic leukaemia (T-PLL).
  • All AITL, HSTCL and T-PLL cases were CD52-positive and the frequency of CD52 expression was high in PTCL-NOS (92.3%), ATLL (94.1%) and CTCL (87.5%), implying a rational role for alemtuzumab in the treatment of these diseases; however, CD52 expression was low in ALCL (50%) and ENT/NKCL (25%).
  • FC testing for cell surface expression of CD52 is indicated in patients with T/NK cell malignancies being considered for alemtuzumab therapy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antigens, CD / analysis. Antigens, Neoplasm / analysis. Antineoplastic Agents / therapeutic use. Glycoproteins / analysis. Lymphoma, T-Cell / immunology
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Antigens, CD30 / analysis. Case-Control Studies. Flow Cytometry / methods. Humans. Immunophenotyping / methods. Killer Cells, Natural / immunology. Lymphoma, Extranodal NK-T-Cell / immunology. Prospective Studies. T-Lymphocytes / immunology. Treatment Failure

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2001 Sep 15;98(6):1721-6 [11535503.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2316-23 [17581918.001]
  • [Cites] Med Oncol. 2002;19 Suppl:S27-32 [12180489.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4267-72 [12543862.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6453-7 [14559836.001]
  • [Cites] Blood. 2004 Jan 15;103(2):428-34 [12969983.001]
  • [Cites] Blood. 2004 Apr 15;103(8):2920-4 [15070664.001]
  • [Cites] Eur J Immunol. 1988 Oct;18(10):1507-14 [2973413.001]
  • [Cites] Tissue Antigens. 1990 Mar;35(3):118-27 [2165283.001]
  • [Cites] Biochem J. 1993 Aug 1;293 ( Pt 3):633-40 [7688956.001]
  • [Cites] Mol Immunol. 1993 Aug;30(12):1089-96 [8366859.001]
  • [Cites] J Biol Chem. 1995 Mar 17;270(11):6088-99 [7890742.001]
  • [Cites] Cytometry. 1996 Oct 1;25(2):113-24 [8891441.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2667-72 [9215839.001]
  • [Cites] Leuk Res. 1998 Feb;22(2):185-91 [9593475.001]
  • [Cites] Biol Blood Marrow Transplant. 2004 Dec;10(12):867-76 [15570255.001]
  • [Cites] Eur J Pharmacol. 2005 May 9;514(2-3):217-24 [15910809.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2005 Sep 29;360(1461):1707-11 [16147535.001]
  • [Cites] Best Pract Res Clin Haematol. 2006;19(4):795-810 [16997184.001]
  • [Cites] Clin Cancer Res. 2006 Dec 1;12(23):7174-9 [17145843.001]
  • [Cites] Cytometry B Clin Cytom. 2007 Jan 15;72(1):34-42 [17051524.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Jun;60(1):129-34 [17406867.001]
  • [Cites] Haematologica. 2007 Apr;92(4):566-7 [17488672.001]
  • [Cites] Oncogene. 2007 May 28;26(25):3644-53 [17530018.001]
  • [Cites] Blood. 2002 May 15;99(10):3554-61 [11986207.001]
  • (PMID = 19236377.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 BC011104-01
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, CD30; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / CD52 antigen; 0 / Glycoproteins; 3A189DH42V / alemtuzumab
  • [Other-IDs] NLM/ NIHMS416345; NLM/ PMC3487105
  •  go-up   go-down


52. Dunleavy K: Angioimmunoblastic T-cell lymphoma (AILT): a unique clinical and pathobiological entity. Onkologie; 2008 Oct;31(10):509-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma (AILT): a unique clinical and pathobiological entity.
  • [MeSH-major] Cardiac Tamponade / diagnosis. Cardiac Tamponade / etiology. Immunoblastic Lymphadenopathy / complications. Immunoblastic Lymphadenopathy / diagnosis. Lymphoma / complications. Lymphoma / diagnosis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Onkologie. 2008 Oct;31(10):546-8 [18854655.001]
  • (PMID = 18854648.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] Switzerland
  •  go-up   go-down


53. Ramasamy K, Lim Z, Pagliuca A, Salisbury JR, Mufti GJ, Devereux S: Successful treatment of refractory angioimmunoblastic T-cell lymphoma with thalidomide and dexamethasone. Haematologica; 2006 Aug;91(8 Suppl):ECR44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of refractory angioimmunoblastic T-cell lymphoma with thalidomide and dexamethasone.
  • Angioimmunoblastic T cell lymphoma (AITL) is a peripheral T-cell lymphoma characterized morphologically by lymphadenopathy with a polymorphic infiltrate, marked vascular and follicular dendritic cell proliferation.
  • Patients usually present with advanced disease and the overall prognosis is poor.
  • [MeSH-major] Dexamethasone / therapeutic use. Lymphoma, T-Cell, Peripheral / drug therapy. Thalidomide / therapeutic use

  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16923528.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 4Z8R6ORS6L / Thalidomide; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


54. Doty JD, Mazur JE, Judson MA: Treatment of sarcoidosis with infliximab. Chest; 2005 Mar;127(3):1064-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/OBJECTIVES: Many patients with sarcoidosis are unable to tolerate corticosteroids or alternative therapeutic agents due to side effects or have disease refractory to these agents.
  • A drug reaction developed in one patient after several months of therapy, oral candidiasis developed in one patient, and angioimmunoblastic lymphoma developed in another patient.

  • Genetic Alliance. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Infliximab .
  • Hazardous Substances Data Bank. PREDNISONE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15764796.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Glucocorticoids; 0 / Tumor Necrosis Factor-alpha; B72HH48FLU / Infliximab; VB0R961HZT / Prednisone
  •  go-up   go-down


56. Decouvelaere AV, Morschhauser F, Buob D, Copin MC, Dumontet C: Heterogeneity of protein kinase C beta(2) expression in lymphoid malignancies. Histopathology; 2007 Apr;50(5):561-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: Protein kinase C (PKC) beta is an important regulator of lymphoid survival and its expression has been shown to be altered in lymphomas.
  • The aim was to determine the expression of PKC beta(2) in various subtypes of lymphoproliferative diseases by immunohistochemistry.
  • METHODS AND RESULTS: One hundred and forty archival samples representing various subtypes of lymphoproliferative diseases were analysed.
  • Certain subtypes, such as mantle cell, lymphocytic or follicular lymphoma, were found to express PKC beta(2) in > 90% of the samples.
  • In follicular lymphomas, the follicular lymphomatous areas were constantly labelled, whereas residual germinal centres remained negative.
  • Most angioimmunoblastic T-cell lymphomas, lymphoblastic T-cell lymphomas and marginal zone/mucosa-associated lymphoid tissue (MALT) lymphomas were labelled with anti-PKC betaII antibody, but the pattern of expression was more heterogeneous in these subtypes.
  • A minority of diffuse large B-cell lymphomas were stained and most plasma cell malignancies were negative.
  • None of the cases of Hodgkin's disease and anaplastic large cell lymphoma expressed PKC beta(2).
  • CONCLUSIONS: PKC beta(2) expression varies significantly among lymphoproliferative diseases.
  • In our series, the highest level of expression was found in mantle cell lymphomas and chronic lymphocytic lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17394491.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Isoenzymes; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.13 / Protein Kinase C beta
  •  go-up   go-down


57. Welch KD, Wen B, Goodlett DR, Yi EC, Lee H, Reilly TP, Nelson SD, Pohl LR: Proteomic identification of potential susceptibility factors in drug-induced liver disease. Chem Res Toxicol; 2005 Jun;18(6):924-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic identification of potential susceptibility factors in drug-induced liver disease.
  • Drug-induced liver disease (DILD) causes significant morbidity and mortality and impairs new drug development.
  • As an approach to better understand the multifactorial basis of DILD, we compared the hepatic proteome of mice that are resistant (SJL) and susceptible (C57Bl/6) to APAP-induced liver disease (AILD), using solution-based isotope-coded affinity tag (ICAT) liquid chromatography mass spectrometry.
  • Several novel factors were identified that were more highly expressed in the livers of SJL mice, including those involved in stress response, cell proliferation and tissue regeneration, and protein modification, implicating these proteins as potential hepatoprotective factors.
  • There was also a selective loss of several mitochondrial proteins from the livers of the susceptible C57Bl/6 mice, suggesting that the loss of functional mitochondria may indeed play a role in AILD.
  • [MeSH-minor] Acetaminophen / toxicity. Affinity Labels / chemistry. Animals. Chromatography, Affinity. Disease Susceptibility / metabolism. Drug Resistance. Liver Diseases / metabolism. Liver Diseases / mortality. Male. Mass Spectrometry. Mice. Mice, Inbred C57BL. Mitochondria, Liver / drug effects. Mitochondria, Liver / metabolism. Species Specificity

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ACETAMINOPHEN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15962927.001).
  • [ISSN] 0893-228X
  • [Journal-full-title] Chemical research in toxicology
  • [ISO-abbreviation] Chem. Res. Toxicol.
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES 07033; United States / NCRR NIH HHS / RR / P51 RR 00166
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Affinity Labels; 362O9ITL9D / Acetaminophen
  •  go-up   go-down


58. Blom E, Heyning FH, Kroes WG: A case of angioimmunoblastic T-cell non-Hodgkin lymphoma with a neocentric inv dup(1). Cancer Genet Cytogenet; 2010 Oct 1;202(1):38-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of angioimmunoblastic T-cell non-Hodgkin lymphoma with a neocentric inv dup(1).
  • Acquired neocentromeres have been described in a particular class of lipomatous tumors (atypical lipomas and well-differentiated liposarcomas; ALP-WDLPS), three cases of acute myeloid leukemia (AML), one case of non-Hodgkin lymphoma (NHL), and one case of lung carcinoma.
  • Here, we report on a 66-year-old male with angioimmunoblastic T-cell NHL.
  • It represented an inverted duplication of the segments between 1q21 and 1qter with a neocentromere in band 1q31.
  • To our knowledge, this is the second reported case of NHL (both T-cell) with the presence of a neocentromere.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromosome Inversion. Chromosomes, Human, Pair 1. Gene Duplication. Immunoblastic Lymphadenopathy / genetics. Lymphoma, T-Cell / genetics
  • [MeSH-minor] Aged. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Male. Neoplasms, Second Primary. Prednisone / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20804919.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


59. Skugor ND, Perić Z, Vrhovac R, Radić-Kristo D, Kardum-Skelin I, Jaksić B: Diffuse large B-cell lymphoma in patient after treatment of angioimmunoblastic T-cell lymphoma. Coll Antropol; 2010 Mar;34(1):241-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma in patient after treatment of angioimmunoblastic T-cell lymphoma.
  • Relatively few cases of Epstein-Barr (EBV)-positive B-cell lymphomas arising in patients with angioimmunoblastic T-cell lymphoma (AITL) have been reported.
  • We report a case of AITL in which diffuse large B-cell lymphoma arose 13 months after the initial diagnosis of AITL.
  • In a 36-year-old female patient, evaluated for moderate leukocytosis, peripheral and abdominal lymphadenopathy AITL was diagnosed in March 2008, based on results of fine-needle aspiration cytology (FNAC) of the enlarged cervical and supraclavicular lymph nodes.
  • The diagnosis was also confirmed by immunophenotyping and histopathology of the cervical lymph nodes.
  • The patient initially recieved FED chemotherapy (fludarabine, cyclophosphamide, dexamethasone) followed by elective autologous hematopoietic stem cell transplantation.
  • In April 2009 the patient was hospitalized because of fever, pancytopenia, hyperbilirubinemia and peripheral lymphadenopathy.
  • CHOP-R chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab) was then administered, resulting in good partial response of the disease.
  • Reduced intensity allogeneic stem cell transplantation performed thereafter, resulted in complete remission of the disease.
  • AITL is a rare lymphoproliferative disorder in which the neoplastic T-cells represent the minority of the lymph node cell population and almost all cases harbor EBV-infected B-cells.
  • Various authors postulated that immunodeficiency in AITL patients together with immunosuppressive effects of cytotoxic drugs, may be responsible for EBV-induced proliferation of latently or newly EBV-infected B-cells with eventual clonal selection and progression to aggressive B-cell lymphoma.
  • [MeSH-major] Immunoblastic Lymphadenopathy / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, T-Cell, Peripheral / pathology. Neoplasms, Second Primary / pathology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20432757.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


60. Nakashima M, Suzuki K, Okada M, Takada K, Kobayashi H, Hama Y: Successful coil embolization of a ruptured hepatic aneurysm in a patient with polyarteritis nodosa accompanied by angioimmunoblastic T cell lymphoma. Clin Rheumatol; 2007 Aug;26(8):1362-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful coil embolization of a ruptured hepatic aneurysm in a patient with polyarteritis nodosa accompanied by angioimmunoblastic T cell lymphoma.
  • Polyarteritis nodosa (PN) occasionally develops in association with malignant disorders.
  • A biopsy of the right inguinal lymph node demonstrated angioimmunoblastic T cell lymphoma (AITL).
  • [MeSH-major] Aneurysm, Ruptured / therapy. Embolization, Therapeutic. Hepatic Artery / pathology. Immunoblastic Lymphadenopathy / complications. Polyarteritis Nodosa / complications
  • [MeSH-minor] Aged. Humans. Lymphoma, T-Cell / complications. Lymphoma, T-Cell / pathology. Male

  • Genetic Alliance. consumer health - Polyarteritis nodosa.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arthritis Rheum. 1994 Feb;37(2):187-92 [8129773.001]
  • [Cites] Arthritis Rheum. 1990 Aug;33(8):1088-93 [1975174.001]
  • [Cites] Cancer. 1987 Jan 15;59(2):208-12 [3802012.001]
  • [Cites] Acta Haematol. 1996;96(2):68-72 [8701703.001]
  • [Cites] Ann Intern Med. 1978 Nov;89(5 Pt 1):660-76 [31121.001]
  • [Cites] J Vasc Surg. 2004 May;39(5):1122-4 [15111872.001]
  • [Cites] J Intern Med. 1994 Dec;236(6):679-83 [7989904.001]
  • (PMID = 17106619.001).
  • [ISSN] 0770-3198
  • [Journal-full-title] Clinical rheumatology
  • [ISO-abbreviation] Clin. Rheumatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


61. Sakai H, Tanaka H, Katsurada T, Yoshida Y, Okamoto E, Ohno H: Angioimmunoblastic T-cell lymphoma initially presenting with replacement of bone marrow and peripheral plasmacytosis. Intern Med; 2007;46(7):419-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma initially presenting with replacement of bone marrow and peripheral plasmacytosis.
  • A 73-year-old man presented with lymphadenopathy, hepatosplenomegaly, and a variety of hematological and immunological abnormalities.
  • Circulating lymphoplasmacytic/immunoblastic cells showed an early plasma cell immunophenotype on flow cytometric analysis.
  • Combination of these observations indicated that the underlying disorder of this patient was angioimmunoblastic T-cell lymphoma (AITL); postmortem pathology was consistent with progression of peripheral T-cell lymphoma.
  • Even in the absence of definitive lymph node biopsy, the appearance of the bone marrow and the peripheral blood can lead to the diagnosis of AITL.
  • [MeSH-major] Bone Marrow / pathology. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell, Peripheral / pathology. Plasma Cells / pathology
  • [MeSH-minor] Aged. Autopsy. Biopsy, Needle. Diagnosis, Differential. Disease Progression. Fatal Outcome. Humans. Immunohistochemistry. Male. Risk Assessment. Severity of Illness Index

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409610.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


62. Kang HY, Hwang JH, Park YS, Bang SM, Lee JS, Chung JH, Kim H: Angioimmunoblastic T-cell lymphoma mimicking Crohn's disease. Dig Dis Sci; 2007 Oct;52(10):2743-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma mimicking Crohn's disease.
  • [MeSH-major] Crohn Disease / diagnosis. Immunoblastic Lymphadenopathy / diagnosis. Lymphoma, T-Cell / diagnosis
  • [MeSH-minor] Biopsy, Needle. Dexamethasone / therapeutic use. Diagnosis, Differential. Drug Therapy, Combination. Female. Follow-Up Studies. Glucocorticoids / therapeutic use. Humans. Immunosuppressive Agents / therapeutic use. Methotrexate / therapeutic use. Middle Aged. Severity of Illness Index. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 1994;424(6):593-600 [8055152.001]
  • [Cites] Leuk Lymphoma. 1999 Feb;32(5-6):545-52 [10048427.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):681-91 [12780782.001]
  • [Cites] N Engl J Med. 1975 Jan 2;292(1):1-8 [1078547.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Cancer. 1988 Jun 1;61(11):2244-50 [3365652.001]
  • [Cites] Pathol Res Pract. 2003;199(8):539-45 [14533938.001]
  • [Cites] Blood. 2002 Jan 15;99(2):627-33 [11781247.001]
  • [Cites] Ann Intern Med. 1992 Sep 1;117(5):364-70 [1380221.001]
  • [Cites] Cancer. 1992 Mar 1;69(5):1259-67 [1739925.001]
  • [Cites] Curr Opin Gastroenterol. 2005 Jan;21(1):80-4 [15687889.001]
  • [Cites] Ann Oncol. 1995 Sep;6(7):659-64 [8664186.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):140-9 [11863096.001]
  • [Cites] Lancet. 1974 Jun 1;1(7866):1070-3 [4135245.001]
  • [Cites] Hepatogastroenterology. 2002 Jul-Aug;49(46):950-4 [12143251.001]
  • [Cites] Am J Pathol. 1988 Dec;133(3):549-56 [2849301.001]
  • [Cites] Gastrointest Endosc. 2003 Mar;57(3):343-7 [12612513.001]
  • [Cites] Haematologica. 2003 Nov;88(11):1272-8 [14607756.001]
  • (PMID = 17394065.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Immunosuppressive Agents; 7S5I7G3JQL / Dexamethasone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


63. Tang XF, Li GD, Li YL, Liang DN, Xia T, Zhou JY, Yao YQ, Wu WQ, Wang ZG, Yang YH, Tang XB, Bai YQ, Ding Q: [Expressions of CXCL13, CD10 and bcl-6 in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified]. Zhonghua Bing Li Xue Za Zhi; 2009 Apr;38(4):224-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expressions of CXCL13, CD10 and bcl-6 in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified].
  • OBJECTIVE: To study the value of immunomarkers CXCL13, CD10, bcl-6 in pathologic diagnosis of angioimmunoblastic T-cell lymphoma (AITL).
  • METHODS: One hundred and fifteen cases of AITL, 30 cases of peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) and 30 cases of reactive lymph nodes with paracortical hyperplasia (RH) encountered during the period from January, 1990 to January, 2008 were retrieved from the archival files of the Department of Pathology, West China Hospital of Sichuan University, China.
  • The morphologic features were reviewed and compared.
  • RESULTS: Regressed follicles were evident in 7.8% (9/115) of AITL cases, 6.7% (2/30) of PTCL, NOS cases and 83.3% (25/30) of RH cases, respectively.
  • A marked increase of number of arborizing venules was shown in 98.3% (113/115) of AITL cases, 63.3% (19/30) of PTCL, NOS cases and 76.7% (23/30) of RH cases, respectively.
  • In AITL, 96.5% (111/115) of cases showed CXCL13 expression, in contrast to 26.7% (8/30) of PTCL, NOS.
  • Expression of CD10 and bcl-6 were found in the neoplastic cells in 50.4% (58/115) and 78.3% (90/115) of AITL, and 3.3% (1/30) and 3.3% (1/30) of PTCL, NOS, respectively.
  • CONCLUSIONS: AITL is a type of lymphoma originated from the follicular helper T cells.
  • Detailed morphologic assessment and use of immunohistochemical markers are essential for accurate diagnosis.
  • [MeSH-major] Chemokine CXCL13 / metabolism. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell, Peripheral / pathology. Neprilysin / metabolism. Proto-Oncogene Proteins c-bcl-6 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Humans. Lymph Nodes / metabolism. Lymph Nodes / pathology. Male. Middle Aged. Pseudolymphoma / metabolism. Pseudolymphoma / pathology

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575892.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 0 / Proto-Oncogene Proteins c-bcl-6; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


64. Willenbrock K, Renné C, Gaulard P, Hansmann ML: In angioimmunoblastic T-cell lymphoma, neoplastic T cells may be a minor cell population. A molecular single-cell and immunohistochemical study. Virchows Arch; 2005 Jan;446(1):15-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In angioimmunoblastic T-cell lymphoma, neoplastic T cells may be a minor cell population. A molecular single-cell and immunohistochemical study.
  • The significance of T-cell proliferations in angioimmunoblastic lymphoma (AILD) is still enigmatic.
  • Although classified as a malignant T-cell lymphoma in the World Health Organisation lymphoma classification, some cases of AILD lack dominant T-cell clones.
  • In a previous study, based on single-cell polymerase chain reaction (PCR), we obtained similar results as studies of AILD using Southern blot or conventional PCR: some cases of AILD contained large T-cell clones, and, in other cases, T-cell clones were undetectable.
  • As in single-cell studies, only a limited number of cells could be investigated; thus, we wanted to gain more insight into the amount and distribution of tumour cells.
  • By applying triple immunofluorescent staining with antibodies directed against T-cell receptor Vbeta-family-specific epitopes, we investigated T-cell populations in AILD and their localisation in the tissue in relation to B cells (CD20) and follicular dendritic cells (CD21).
  • [MeSH-major] Immunoblastic Lymphadenopathy / immunology. Lymphoma, T-Cell / immunology. T-Lymphocytes / pathology
  • [MeSH-minor] Antigens, CD20 / analysis. Fluorescent Antibody Technique. Humans. Immunohistochemistry. Polymerase Chain Reaction. Receptors, Antigen, T-Cell, alpha-beta / analysis. Receptors, Complement 3d / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 1994;424(6):593-600 [8055152.001]
  • [Cites] Leuk Lymphoma. 2000 Aug;38(5-6):541-5 [10953975.001]
  • [Cites] N Engl J Med. 1975 Jan 2;292(1):1-8 [1078547.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):661-9 [10666395.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):1067-71 [10702422.001]
  • [Cites] Blood. 1995 May 15;85(10):2862-9 [7742548.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1851-7 [11337383.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10962-6 [7971992.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1985;406(1):105-24 [3922106.001]
  • [Cites] EMBO J. 1993 Dec 15;12(13):4955-67 [8262038.001]
  • [Cites] J Exp Med. 1996 Oct 1;184(4):1495-505 [8879220.001]
  • [Cites] Eur J Immunol. 1998 Aug;28(8):2424-31 [9710220.001]
  • [Cites] Blood. 1994 Jul 15;84(2):574-81 [8025283.001]
  • [Cites] Leukemia. 1997 Jul;11(7):1055-62 [9204991.001]
  • [Cites] Lancet. 1974 Jun 1;1(7866):1070-3 [4135245.001]
  • [Cites] Am J Pathol. 1988 Dec;133(3):549-56 [2849301.001]
  • [Cites] Am J Pathol. 1986 Mar;122(3):392-7 [3082212.001]
  • [Cites] Dtsch Med Wochenschr. 1975 May 23;100(21):1157-63 [1132324.001]
  • (PMID = 15480765.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Receptors, Antigen, T-Cell, alpha-beta; 0 / Receptors, Complement 3d
  •  go-up   go-down


65. Zhou Y, Attygalle AD, Chuang SS, Diss T, Ye H, Liu H, Hamoudi RA, Munson P, Bacon CM, Dogan A, Du MQ: Angioimmunoblastic T-cell lymphoma: histological progression associates with EBV and HHV6B viral load. Br J Haematol; 2007 Jul;138(1):44-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma: histological progression associates with EBV and HHV6B viral load.
  • The clinical and histological presentations of angioimmunoblastic T-cell lymphoma (AITL) often mimic an infectious process.
  • High EBV load was also significantly associated with B-cell monoclonality.
  • Our results demonstrate an association between EBV and HHV6B infection and the histological progression of AITL, suggesting that these viruses may play a role in the pathogenesis of this lymphoma.
  • [MeSH-major] Herpesvirus 4, Human / pathogenicity. Herpesvirus 6, Human / pathogenicity. Infectious Mononucleosis / complications. Lymphoma, Large-Cell, Immunoblastic / virology. Roseolovirus Infections / complications. Tumor Virus Infections / complications
  • [MeSH-minor] Antigens, CD20 / analysis. Antigens, CD79 / analysis. Chi-Square Distribution. Disease Progression. Genes, Viral. Humans. Immunohistochemistry. Immunophenotyping. In Situ Hybridization. Neprilysin / analysis. Polymerase Chain Reaction / methods. Viral Load

  • MedlinePlus Health Information. consumer health - Infectious Mononucleosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17555446.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD79; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


66. Basu D, Bundele M: Angioimmunoblastic T-cell lymphoma obscured by concomitant florid epithelioid cell granulomatous reaction--a case report. Indian J Pathol Microbiol; 2005 Oct;48(4):500-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma obscured by concomitant florid epithelioid cell granulomatous reaction--a case report.
  • Epithelioid cell granuloma occurs in association with many neoplasms including lymphoma.
  • However they have rarely obscured the microscopic features of a lymphoma.
  • We report on a case where a florid epithelioid cell granulomatous reaction caused difficulty in interpretation and delayed the final diagnosis of a case of peripheral T cell lymphoma of the angioimmunoblastic type.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / pathology
  • [MeSH-minor] Diagnosis, Differential. Epithelioid Cells / pathology. Granuloma / pathology. Humans. Immunoblastic Lymphadenopathy / pathology. Lymphadenitis / diagnosis. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16366110.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


67. Xerri L, Chetaille B, Serriari N, Attias C, Guillaume Y, Arnoulet C, Olive D: Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. Hum Pathol; 2008 Jul;39(7):1050-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia.
  • PD-1 expression was recently reported in some T-cell non-Hodgkin lymphoma (NHL) subtypes, but the expression profile of PD-1 and its ligands (PD-L1 and PD-L2) in B-NHLs remains largely to be characterized.
  • A series of 161 lymphoma tissue and 11 blood samples was analyzed using either immunohistochemistry or flow cytometry.
  • In B-NHLs, PD-1 was mainly expressed in reactive T cells; but expression was also noted in neoplastic B cells from small lymphocytic lymphoma (SLL, 12/13), grade III follicular lymphoma (3/3), and diffuse large cell lymphoma (2/25).
  • In contrast, neoplastic B cells from mantle cell lymphoma (0/11), marginal zone lymphoma (0/12), Burkitt lymphoma (0/3), and grade 1 to 2 follicular lymphoma (0/40) were PD-1 negative.
  • PD-L1 and PD-L2 were negative in small B-cell lymphomas, including B-SLL.
  • PD-1 expression in T-NHLs was restricted to the angioimmunoblastic subtype (8/8).
  • Because the anti-PD-1.6.4 antibody works on paraffin sections, it represents a useful tool to differentiate SLL/CLL from other small B-cell lymphomas.
  • [MeSH-major] Antigens, CD / metabolism. Apoptosis Regulatory Proteins / metabolism. Biomarkers, Tumor / metabolism. Immunoblastic Lymphadenopathy / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Lymphoma, T-Cell / metabolism
  • [MeSH-minor] Animals. Diagnosis, Differential. Flow Cytometry. Lymph Nodes / metabolism. Lymph Nodes / pathology. Mice. Mice, Inbred BALB C. Programmed Cell Death 1 Receptor

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Hum Pathol. 2010 Nov;41(11):1655. Seriari, Nacer [corrected to Serriari, Nacer]
  • (PMID = 18479731.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Apoptosis Regulatory Proteins; 0 / Biomarkers, Tumor; 0 / PDCD1 protein, human; 0 / Programmed Cell Death 1 Receptor
  •  go-up   go-down


68. Matsui K, Adachi M, Tominaga T, Shinohara K, Kamei T: Angioimmunoblastic T cell lymphoma associated with reversible myelofibrosis. Intern Med; 2008;47(21):1921-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T cell lymphoma associated with reversible myelofibrosis.
  • Biopsy of the lymph node demonstrated angioimmunoblastic T cell lymphoma (AITL) with the loss of normal architecture, proliferation of neoplastic T cells, small vessels mixed with eosinophils and plasma cells.
  • After chemotherapy, remission of lymphoma was achieved.
  • [MeSH-major] Immunoblastic Lymphadenopathy / diagnosis. Primary Myelofibrosis / diagnosis
  • [MeSH-minor] Humans. Lymphoma, T-Cell / complications. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / drug therapy. Male. Middle Aged

  • Genetic Alliance. consumer health - Myelofibrosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18981638.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


69. Woda BA: Hypersensitivity pneumonitis: an immunopathology review. Arch Pathol Lab Med; 2008 Feb;132(2):204-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Hypersensitivity pneumonitis (HSP) is an immunologically mediated alveolar and interstitial lung disease caused by repeated inhalation of organic dusts and some occupational agents.
  • A number of unexplained features of HSP remain, namely (1) why do so few exposed individuals develop clinical HSP, (2) what triggers an acute episode after prolonged periods of previous sensitization, and (3) what leads to disease progression.
  • CONCLUSIONS: Current data suggest that individuals with a T(H)1 dominant response are likely to develop clinical disease.
  • There is also some evidence that genetic factors such as polymorphisms in the major histocompatibility complex, tumor necrosis factor alpha, and tissue inhibitor of metalloproteinase 3 are associated with the development of or resistance to the disease.
  • [MeSH-minor] Genetic Predisposition to Disease. Humans. Killer Cells, Natural / immunology. Lung / immunology. Lung / pathology. T-Lymphocyte Subsets / immunology. Th1 Cells / immunology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18251577.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 27
  •  go-up   go-down


70. Notas G, Xylouri I, Kritikos H, Stavroulaki E, Roditakis G, Boumpas D: A rare case of angioimmunoblastic T-cell lymphoma presenting with fever and late polyarthritis. Rheumatology (Oxford); 2009 Jul;48(7):859-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of angioimmunoblastic T-cell lymphoma presenting with fever and late polyarthritis.
  • [MeSH-major] Lymphoma, T-Cell / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19435859.001).
  • [ISSN] 1462-0332
  • [Journal-full-title] Rheumatology (Oxford, England)
  • [ISO-abbreviation] Rheumatology (Oxford)
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


71. Halene S, Zieske A, Berliner N: Sustained remission from angioimmunoblastic T-cell lymphoma induced by alemtuzumab. Nat Clin Pract Oncol; 2006 Mar;3(3):165-8; quiz 169
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained remission from angioimmunoblastic T-cell lymphoma induced by alemtuzumab.
  • She had previously had a positive protein derivative test with a negative chest X-ray; her medical history was also remarkable for a mitral valve prolapse.
  • Initial symptoms resolved spontaneously without therapy, but fever recurred with associated arthralgias, myalgias, diffuse and worsening lymphadenopathy, splenomegaly, and bilateral pulmonary infiltrates.
  • DIAGNOSIS: Angioimmunoblastic T-cell lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Immunoblastic Lymphadenopathy / drug therapy. Lymphoma, T-Cell / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16520806.001).
  • [ISSN] 1743-4254
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  •  go-up   go-down


72. Choi JH, Oh YH, Park IK: A case of pure red cell aplasia associated with angioimmunoblastic T-cell lymphoma. Cancer Res Treat; 2010 Jun;42(2):115-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of pure red cell aplasia associated with angioimmunoblastic T-cell lymphoma.
  • Pure red cell aplasia is a bone marrow failure characterized by a progressive normocytic anemia and reticulocytopenia without leucopenia and thrombocytopenia.
  • It is associated with various hematologic diseases.
  • However, pure red cell aplasia with angioimmunoblastic T cell lymphoma has rarely been reported.
  • Here we describe a 43-year-old woman with pure red cell aplasia associated with angioimmunoblastic T-cell lymphoma.
  • A CT scan of the abdomen revealed marked hepatosplenomegaly and small multiple lymphadenopathies.
  • A bone marrow biopsy revealed focal infiltration of abnormal lymphoid cells and absence of red cell precursors.
  • Splenic biopsy was compatible with angioimmunoblastic T-cell lymphoma.
  • Ultimately, diagnosis of pure red cell aplasia associated with angioimmunoblastic T-cell lymphoma was made.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Haematol. 1996;96(2):68-72 [8701703.001]
  • [Cites] Am J Hematol. 1994 Jun;46(2):72-8 [8172198.001]
  • [Cites] J R Soc Med. 1983 Oct;76(10):894-5 [6631867.001]
  • [Cites] Am J Hematol. 1999 Dec;62(4):259-60 [10589086.001]
  • [Cites] Biomed Pharmacother. 2003 Oct;57(8):326-32 [14568226.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):681-91 [12780782.001]
  • [Cites] Haematologica. 1982 Nov-Dec;67(6):919-25 [6819197.001]
  • (PMID = 20622966.001).
  • [ISSN] 2005-9256
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2901080
  • [Keywords] NOTNLM ; Lymphoma / Pure / Red-cell aplasia / T-cell
  •  go-up   go-down


73. Jayarajan J, Azad A: A rare cause of bilateral parotid enlargement: angioimmunoblastic T-cell lymphoma. ANZ J Surg; 2009 Oct;79(10):769
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare cause of bilateral parotid enlargement: angioimmunoblastic T-cell lymphoma.
  • [MeSH-major] Lymphoma, Large-Cell, Immunoblastic / diagnosis. Parotid Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19878191.001).
  • [ISSN] 1445-2197
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Australia
  •  go-up   go-down


74. Niino D, Komohara Y, Murayama T, Aoki R, Kimura Y, Hashikawa K, Kiyasu J, Takeuchi M, Suefuji N, Sugita Y, Takeya M, Ohshima K: Ratio of M2 macrophage expression is closely associated with poor prognosis for Angioimmunoblastic T-cell lymphoma (AITL). Pathol Int; 2010 Apr;60(4):278-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ratio of M2 macrophage expression is closely associated with poor prognosis for Angioimmunoblastic T-cell lymphoma (AITL).
  • Angioimmunoblastic T-cell lymphoma (AITL) is a peripheral T-cell lymphoma characterized by systemic disease with polymorphous infiltrate including macrophages.
  • Although many studies of tumor-associated macrophage (TAM) populations in various malignant tumors have been published, only a few have dealt with activation of macrophage phenotypes such as M1 and M2 in tumor tissue.
  • [MeSH-major] Antigens, Differentiation, Myelomonocytic / immunology. Lymphoma, T-Cell, Peripheral / immunology. Lymphoma, T-Cell, Peripheral / mortality. Macrophages / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunoblastic Lymphadenopathy / immunology. Immunoblastic Lymphadenopathy / pathology. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis. Severity of Illness Index. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20403029.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, Differentiation, Myelomonocytic
  •  go-up   go-down


75. Stacchini A, Demurtas A, Aliberti S, Francia di Celle P, Godio L, Palestro G, Novero D: The usefulness of flow cytometric CD10 detection in the differential diagnosis of peripheral T-cell lymphomas. Am J Clin Pathol; 2007 Nov;128(5):854-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The usefulness of flow cytometric CD10 detection in the differential diagnosis of peripheral T-cell lymphomas.
  • We studied the histologic and multiparameter flow cytometry (MFC) features of 12 cases of angioimmunoblastic T-cell lymphoma (AITL), 13 of mature T-cell lymphoma, and 25 control cases of reactive lymphoid hyperplasia to evaluate the role of CD10 in the differential diagnosis of peripheral T-cell lymphomas (PTCLs).
  • Mature T-cell lymphoma showed a more heterogeneous altered immunophenotypic pattern, and 2 cases of PTCL, unspecified, had clear evidence of aberrant CD10 expression on T cells.
  • A small physiologic CD3+/CD4+/CD10+ T-cell population was detected by MFC in all control cases tested (range, 0.28%-4.71%), suggesting that a normal subset of peripheral CD10+ T cells exists.
  • CD10 was a highly sensitive but incompletely specific phenotypic marker for diagnosing AITL; the differential diagnosis of PTCL, unspecified, must be related with traditional histologic features.
  • [MeSH-major] Flow Cytometry / methods. Lymphoma, T-Cell, Peripheral / chemistry. Lymphoma, T-Cell, Peripheral / diagnosis. Neprilysin / analysis
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Diagnosis, Differential. Female. Humans. Immunoblastic Lymphadenopathy / diagnosis. Immunophenotyping. Lymph Nodes / pathology. Male. Middle Aged. Pseudolymphoma / diagnosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17951210.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


76. Hawley RC, Cankovic M, Zarbo RJ: Angioimmunoblastic T-cell lymphoma with supervening Epstein-Barr virus-associated large B-cell lymphoma. Arch Pathol Lab Med; 2006 Nov;130(11):1707-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma with supervening Epstein-Barr virus-associated large B-cell lymphoma.
  • Patients with angioimmunoblastic T-cell lymphoma can have profound immune dysfunction and immunodeficiency.
  • Epstein-Barr virus-driven B-cell lymphoid proliferation can occur in angioimmunoblastic T-cell lymphoma, as in other immunodeficiency states.
  • However, few cases of Epstein-Barr virus-positive B-cell lymphoma arising in patients with preexisting angioimmunoblastic T-cell lymphoma have been reported.
  • We report a case of angioimmunoblastic T-cell lymphoma in which diffuse large B-cell lymphoma developed 56 months after the diagnosis of angioimmunoblastic T-cell lymphoma.
  • The patient survived for 9 years after the initial diagnosis of angioimmunoblastic T-cell lymphoma, and molecular studies performed on multiple biopsy specimens during this period revealed the dynamic nature of clonal lymphoid expansion.
  • Epstein-Barr virus latent membrane protein 1 and Epstein-Barr virus-encoded RNA were detected in the diffuse large B-cell lymphoma, suggesting that Epstein-Barr virus may have played a role in the pathogenesis of the diffuse large B-cell lymphoma.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Immunoblastic Lymphadenopathy / complications. Immunoblastic Lymphadenopathy / pathology. Lymphoma, B-Cell / complications. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / virology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17076535.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / RNA, Viral; 0 / Viral Matrix Proteins
  •  go-up   go-down


77. Yee SB, Bourdi M, Masson MJ, Pohl LR: Hepatoprotective role of endogenous interleukin-13 in a murine model of acetaminophen-induced liver disease. Chem Res Toxicol; 2007 May;20(5):734-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatoprotective role of endogenous interleukin-13 in a murine model of acetaminophen-induced liver disease.
  • Recent evidence suggests that a deficiency in one or more hepatoprotective regulatory mechanisms may contribute to determining susceptibility in drug-induced liver disease.
  • In the present study, we investigated the role of interleukin (IL)-13 in acetaminophen (APAP)-induced liver disease (AILD).
  • Following APAP (200 mg/kg) administration to male C57BL/6 wild-type (WT) mice, hepatotoxicity developed up to 24 h post-APAP, with a concomitant increase in serum IL-13 concentration.
  • No difference was observed in either overall APAP-protein adduct formation or liver glutathione levels between KO and WT mice following APAP administration, suggesting that the increased susceptibility of IL-13 KO mice to AILD was not due to enhanced APAP bioactivation but rather injurious downstream events.
  • In this regard, multiplex antibody arrays were used to identify potential IL-13-regulated biomarkers, including various cytokines and chemokines, as well as nitric oxide (NO), associated with AILD that were present at higher concentrations in the sera of APAP-treated IL-13 KO mice than in WT mice.
  • Subsequent inhibition studies determined interferon-gamma, NO, neutrophils, natural killer cells, and natural killer cells with T-cell receptors had pathologic roles in AILD in IL-13 KO mice.
  • Taken together, these results suggest that IL-13 is a critical hepatoprotective factor modulating the susceptibility to AILD and may provide hepatoprotection, in part, by down-regulating protoxicant factors and cells associated with the innate immune system.
  • [MeSH-major] Acetaminophen / toxicity. Analgesics, Non-Narcotic / toxicity. Drug-Induced Liver Injury / prevention & control. Interleukin-13 / blood
  • [MeSH-minor] Alanine Transaminase / blood. Animals. Antibodies, Blocking / pharmacology. Biomarkers / blood. Disease Models, Animal. Drug Synergism. Gene Silencing. Glutathione / metabolism. Liver / drug effects. Liver / metabolism. Liver / pathology. Male. Mice. Mice, Inbred C57BL. Mice, Knockout. Neutrophils / drug effects. Neutrophils / metabolism. Neutrophils / pathology


78. Chen W, Kesler MV, Karandikar NJ, McKenna RW, Kroft SH: Flow cytometric features of angioimmunoblastic T-cell lymphoma. Cytometry B Clin Cytom; 2006 May;70(3):142-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flow cytometric features of angioimmunoblastic T-cell lymphoma.
  • BACKGROUND: The immunophenotypic features of angioimmunoblastic T-cell lymphoma (AILT) have not been well described.
  • METHODS: We retrospectively reviewed our institutional experience with the flow cytometric features of 16 cases of AILT.
  • CD10 was expressed by the neoplastic populations in 11 of 14 cases at diagnosis; in 3 of these 11 only a subpopulation of the neoplastic cells was CD10(+).
  • CONCLUSIONS: These results indicate the potential utility of flow cytometry in the diagnosis and follow-up of AILT.
  • [MeSH-major] Flow Cytometry / methods. Immunoblastic Lymphadenopathy / pathology. Immunophenotyping / methods. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / analysis. Antigens, CD3 / analysis. Antigens, CD45 / analysis. Antigens, CD7 / analysis. Bone Marrow / pathology. Female. Follow-Up Studies. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor / genetics. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neprilysin / analysis. Receptors, Complement 3d / analysis. Retrospective Studies. T-Lymphocytes / chemistry. T-Lymphocytes / metabolism. T-Lymphocytes / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 International Society for Analytical Cytology.
  • (PMID = 16572417.001).
  • [ISSN] 1552-4949
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD3; 0 / Antigens, CD7; 0 / Receptors, Complement 3d; EC 3.1.3.48 / Antigens, CD45; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


79. Howard M, Dogan A: Diagnosis of Nodal Peripheral T-Cell Lymphomas. Surg Pathol Clin; 2010 Dec;3(4):955-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of Nodal Peripheral T-Cell Lymphomas.
  • Lymph node-based peripheral T-cell lymphomas are rare and exhibit a morphologic spectrum that overlaps with reactive lymphoid hyperplasia, B-cell lymphomas, and Hodgkin lymphoma, presenting a diagnostic challenge.
  • This review focuses on the major categories of lymph node-based peripheral T-cell lymphomas recognized by the 2008 World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues.
  • Diagnostic strategies for approaching T-cell neoplasms using a combined clinical, morphologic, immunophenotypic, and genetic approach are presented.
  • Practical information to aid in distinguishing peripheral T-cell lymphomas from other hematologic malignancies and benign conditions is provided.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 26839296.001).
  • [ISSN] 1875-9181
  • [Journal-full-title] Surgical pathology clinics
  • [ISO-abbreviation] Surg Pathol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anaplastic large cell lymphoma / Angioimmunoblastic / Lymph node hyperplasia / T-cell lymphoma
  •  go-up   go-down


80. Jones D: Functional classification of peripheral T-cell lymphomas as an approach to improve outcome prediction and therapy selection. Semin Hematol; 2010 Apr;47 Suppl 1:S1-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional classification of peripheral T-cell lymphomas as an approach to improve outcome prediction and therapy selection.
  • Many types of peripheral T-cell lymphoma (PTCL) are currently classified by the World Health Organization (WHO) based on their predominant site of organ involvement (eg, intestinal or cutaneous types).
  • However, this approach and traditional staging scores such as the IPI can provide limited prognostic information, especially in those PTCL types where morbidity and mortality are primarily related to immune dysregulation and cytokine syndromes driven by the lymphoma cells.
  • These "immune participatory" PTCLs (including, commonly, angioimmunoblastic T-cell lymphoma and many extranodal types) can therefore have poor outcomes even at low tumor burdens.
  • For these reasons, a classification that includes functional profiling of the lymphoma cells may add valuable prognostic information.
  • Such data, including cytokine expression patterns and T-cell receptor signaling pathway activation status, whether normal or abnormal, need to be considered in future classification systems, especially when incorpating targeted therapy.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / classification
  • [MeSH-minor] Cell Differentiation. Humans. Leukemia-Lymphoma, Adult T-Cell / classification. Leukemia-Lymphoma, Adult T-Cell / pathology. Lymphoma, Large-Cell, Anaplastic / classification. Lymphoma, Large-Cell, Anaplastic / pathology. Lymphoma, T-Cell / classification. Lymphoma, T-Cell / pathology. Lymphoproliferative Disorders / classification. Lymphoproliferative Disorders / pathology. Prognosis. Receptors, Antigen, T-Cell / immunology. T-Lymphocytes / pathology. World Health Organization

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20359579.001).
  • [ISSN] 1532-8686
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell
  • [Number-of-references] 13
  •  go-up   go-down


81. Geissinger E, Bonzheim I, Krenács L, Roth S, Ströbel P, Ott G, Reimer P, Wilhelm M, Müller-Hermelink HK, Rüdiger T: Identification of the tumor cells in peripheral T-cell lymphomas by combined polymerase chain reaction-based T-cell receptor beta spectrotyping and immunohistological detection with T-cell receptor beta chain variable region segment-specific antibodies. J Mol Diagn; 2005 Oct;7(4):455-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of the tumor cells in peripheral T-cell lymphomas by combined polymerase chain reaction-based T-cell receptor beta spectrotyping and immunohistological detection with T-cell receptor beta chain variable region segment-specific antibodies.
  • Most nodal peripheral T-cell lymphomas (PTCL) originate from alphabeta-T cells, and they often contain reactive T cells that may hamper immunophenotyping.
  • To specifically identify the neoplastic population in immunohistochemically stained slides, we assessed the heterogeneity of the T-cell receptor beta chain variable region (TCRVbeta).
  • The TCRVbeta segment of the tumor cells was defined in 13 of 13 PTCL not otherwise specified and 11 of 13 angioimmunoblastic T-cell lymphomas.
  • [MeSH-major] Antibodies / immunology. Lymphoma, T-Cell, Peripheral / genetics. Lymphoma, T-Cell, Peripheral / pathology. Polymerase Chain Reaction. Receptors, Antigen, T-Cell, alpha-beta / genetics. Receptors, Antigen, T-Cell, alpha-beta / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1997 Dec;183(4):432-9 [9496260.001]
  • [Cites] Blood. 2001 Jul 1;98(1):165-73 [11418476.001]
  • [Cites] Am J Pathol. 1988 Dec;133(3):549-56 [2849301.001]
  • [Cites] Histopathology. 1988 Jul;13(1):19-41 [3061921.001]
  • [Cites] Am J Clin Pathol. 1989 Feb;91(2):152-8 [2464922.001]
  • [Cites] Br J Cancer. 1988 Dec;58(6):723-9 [2852027.001]
  • [Cites] Am J Pathol. 1990 May;136(5):1093-9 [2161617.001]
  • [Cites] Hum Pathol. 1990 Nov;21(11):1117-25 [2227919.001]
  • [Cites] Cancer. 1991 May 15;67(10):2566-78 [1826629.001]
  • [Cites] Eur J Haematol. 1991 Sep;47(3):168-73 [1915799.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):661-9 [10666395.001]
  • [Cites] Blood. 2000 Jul 15;96(2):640-6 [10887129.001]
  • [Cites] Cytometry. 2000 Aug 1;40(4):336-45 [10918284.001]
  • [Cites] J Immunol. 2000 Aug 15;165(4):2020-7 [10925285.001]
  • [Cites] J Immunol Methods. 2000 Dec 1;246(1-2):131-43 [11121554.001]
  • [Cites] J Histochem Cytochem. 2001 Feb;49(2):139-45 [11156682.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1851-7 [11337383.001]
  • [Cites] Mol Diagn. 2001 Sep;6(3):169-79 [11571710.001]
  • [Cites] Curr Opin Immunol. 2002 Feb;14(1):52-65 [11790533.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):140-9 [11863096.001]
  • [Cites] Pathol Res Pract. 2002;198(6):389-95 [12166895.001]
  • [Cites] Int J Cancer. 2003 Jan 1;103(1):12-20 [12455048.001]
  • [Cites] Hematol J. 2003;4(1):18-25 [12692516.001]
  • [Cites] Am J Clin Pathol. 2003 Nov;120(5):785-94 [14608907.001]
  • [Cites] Virchows Arch. 2004 Oct;445(4):334-43 [15480768.001]
  • [Cites] Blood. 1986 Feb;67(2):474-8 [3080041.001]
  • [Cites] Blood. 1986 Sep;68(3):663-7 [2943330.001]
  • [Cites] Am J Pathol. 1987 Jul;128(1):181-201 [3111266.001]
  • [Cites] Br J Haematol. 1987 Aug;66(4):451-60 [3499166.001]
  • [Cites] Br J Haematol. 1987 Sep;67(1):19-24 [3499172.001]
  • [Cites] Cancer. 1988 May 15;61(10):2060-70 [2896068.001]
  • [Cites] Blood. 1988 Aug;72(2):413-21 [3261178.001]
  • [Cites] Nature. 1988 Aug 4;334(6181):395-402 [3043226.001]
  • [Cites] Blood. 1988 Sep;72(3):1000-6 [3046680.001]
  • [Cites] Int J Cancer. 1992 Jan 21;50(2):186-91 [1730511.001]
  • [Cites] Eur J Immunol. 1992 Feb;22(2):541-9 [1311263.001]
  • [Cites] J Pathol. 1992 Feb;166(2):109-12 [1560311.001]
  • [Cites] Acta Pathol Jpn. 1992 Feb;42(2):141-9 [1314007.001]
  • [Cites] Cancer. 1992 May 15;69(10):2571-82 [1568182.001]
  • [Cites] Hum Immunol. 1992 Sep;35(1):60-7 [1478894.001]
  • [Cites] Leuk Lymphoma. 1992 Aug;7(5-6):449-55 [1493445.001]
  • [Cites] Histopathology. 1993 Apr;22(4):303-10 [8514273.001]
  • [Cites] Acta Pathol Jpn. 1993 Jul-Aug;43(7-8):396-412 [8372685.001]
  • [Cites] Immunol Today. 1993 Aug;14(8):391-4 [8397778.001]
  • [Cites] Leukemia. 1994 Feb;8(2):295-8 [8309253.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Virchows Arch. 1994;425(1):25-32 [7921409.001]
  • [Cites] Hum Immunol. 1995 Jul;43(3):207-18 [7558938.001]
  • [Cites] Immunogenetics. 1995;42(6):451-3 [8550091.001]
  • [Cites] Immunogenetics. 1995;42(6):455-500 [8550092.001]
  • [Cites] Am J Clin Pathol. 1998 May;109(5):610-7 [9576581.001]
  • [Cites] Mod Pathol. 1998 Apr;11(4):313-23 [9578080.001]
  • [Cites] Am J Surg Pathol. 1998 Jun;22(6):643-55 [9630171.001]
  • [Cites] J Biol Chem. 1998 Sep 11;273(37):23709-15 [9726977.001]
  • [Cites] Hum Pathol. 1999 Jan;30(1):48-53 [9923926.001]
  • [Cites] J Immunol Methods. 1999 Apr 22;224(1-2):203-8 [10357220.001]
  • [Cites] Leukemia. 1999 Jun;13(6):965-74 [10360387.001]
  • [Cites] Am J Surg Pathol. 1999 Oct;23(10):1184-200 [10524519.001]
  • [Cites] Br J Dermatol. 1995 Dec;133(6):978-82 [8547055.001]
  • [Cites] Science. 1996 Jun 21;272(5269):1755-62 [8650574.001]
  • [Cites] Science. 1996 Jul 5;273(5271):104-6 [8658175.001]
  • [Cites] Cytometry. 1996 Jun 15;26(2):148-53 [8817091.001]
  • [Cites] Auris Nasus Larynx. 1997 Apr;24(2):199-206 [9134144.001]
  • [Cites] Blood. 1997 Jun 15;89(12):4501-13 [9192774.001]
  • [Cites] Mol Pathol. 1997 Feb;50(1):15-7 [9208808.001]
  • (PMID = 16237215.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, CD3; 0 / Receptors, Antigen, T-Cell, alpha-beta
  • [Other-IDs] NLM/ PMC1885558
  •  go-up   go-down


82. Markou K, Goudakos J, Constantinidis J, Kostopoulos I, Vital V, Nikolaou A: Primary laryngeal lymphoma: report of 3 cases and review of the literature. Head Neck; 2010 Apr;32(4):541-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary laryngeal lymphoma: report of 3 cases and review of the literature.
  • BACKGROUND: Extranodal lymphomas limited to the larynx are rare, accounting for less than 1% of all laryngeal neoplasms.
  • METHODS: The case records of 3 patients with the diagnosis of lymphoma involving the larynx were retrospectively reviewed.
  • RESULTS: The histopathological diagnosis revealed 1 case of marginal zone lymphoma mucosa-associated lymphoid tissue type, 1 case of T-lymphoblastic lymphoma, and 1 case of a rare coexistence of in situ squamous cell carcinoma with an isolated intravascular (angioimmunoblastic) lymphoma of peripheral T-cell origin.
  • CONCLUSIONS: Primary laryngeal lymphoma is a rare entity.
  • Early symptoms are subtle and nonspecific, and confirmation of the diagnosis is often difficult.
  • Because of the rarity of this tumor type, the optimal management remains controversial and it seems that should be managed not as a distinct disease entity but as an unusual presentation of non-Hodgkin lymphoma, according to the recent treatment trends.
  • [MeSH-major] Laryngeal Neoplasms / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Non-Hodgkin / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19378323.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 50
  •  go-up   go-down


83. Chen AI, McMillan A, Negrin RS, Horning SJ, Laport GG: Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience. Biol Blood Marrow Transplant; 2008 Jul;14(7):741-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience.
  • The peripheral T cell lymphomas (PTCL) carry a worse prognosis compared to B cell non-Hodgkin lymphoma.
  • There is no uniform standard therapy for PTCL, and autologous hematopoietic cell transplant (AHCT) is often offered as consolidation in first remission or at relapse because of the poor outcomes with conventional therapy.
  • Fifty-three cases were identified consisting of systemic anaplastic large cell (n = 18), PTCL unspecified (n = 17), angioimmunoblastic (n = 9), nasal type extranodal NK/T (n = 7), hepatosplenic (n = 2), and adult T cell leukemia/lymphoma (n = 1).
  • Fifteen patients were transplanted in first complete or partial response (CR1/PR1), 32 in second or beyond CR or PR (CR2/PR2+), and 11 with primary refractory disease (REF).
  • With a median follow-up was 5 years (range: 1.0-11.5), the 5-year progression-free survival (PFS) and overall survival (OS) were 25% and 48%, respectively.
  • Disease status at AHCT had a significant impact on PFS and OS.
  • The pretransplant factors that impacted survival were disease status and the number of prior regimens.


84. Krenacs L, Schaerli P, Kis G, Bagdi E: Phenotype of neoplastic cells in angioimmunoblastic T-cell lymphoma is consistent with activated follicular B helper T cells. Blood; 2006 Aug 1;108(3):1110-1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phenotype of neoplastic cells in angioimmunoblastic T-cell lymphoma is consistent with activated follicular B helper T cells.
  • [MeSH-major] Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell / pathology. T-Lymphocytes, Helper-Inducer / pathology

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Blood. 2005 Aug 15;106(4):1501-2 [16079436.001]
  • (PMID = 16861359.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


85. Zheng YY, Chen G, Zhou XG, Zhang SH, Zhang YN: [Morphologic and immunophenotypic analysis of angioimmunoblastic T-cell lymphoma]. Zhonghua Bing Li Xue Za Zhi; 2009 Mar;38(3):173-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Morphologic and immunophenotypic analysis of angioimmunoblastic T-cell lymphoma].
  • OBJECTIVE: To study the morphologic and immunophenotypic features of angioimmunoblastic T-cell lymphoma (AITL), as well as the origin of the proliferative follicular dendritic cells (FDCs) in AITL.
  • Cases of peripheral T-cell lymphoma, unspecified, extranodal NK/T-cell lymphoma, nasal-type, enteropathy-type T-cell lymphoma, anaplastic large cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma and reactive lymphoid proliferation were selected as controls.
  • RESULTS: Amongst the 29 cases of AITL studied, 75.9% (22/29) showed aberrant expression of CD10, while all except one of the controlled cases were negative, 82.8% (24/29) of the AITL cases expressed CXCL13, while all cases of peripheral T-cell lymphoma, unspecified were negative.
  • As for bcl-6 staining, although the highest percentage of bcl-6-positive cells was observed in AITL, the expression pattern was not useful in differentiating AITL from peripheral T-cell lymphoma, unspecified and lymphoid reaction.
  • Two of the cases, which contained obvious germinal centers, had the follicular dendritic cell meshwork extending beyond the lymphoid follicles.
  • [MeSH-major] Chemokine CXCL13 / metabolism. Dendritic Cells, Follicular / pathology. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell, Peripheral / pathology. Neprilysin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575853.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 0 / Proto-Oncogene Proteins c-bcl-6; 0 / Receptors, Complement 3d; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


91. Miura N, Suzuki K, Yoshino M, Kitagawa W, Yamada H, Ohtani H, Joh K, Imai H: Acute renal failure due to IgM-lambda glomerular thrombi and MPGN-like lesions in a patient with angioimmunoblastic T-Cell lymphoma. Am J Kidney Dis; 2006 Jul;48(1):e3-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute renal failure due to IgM-lambda glomerular thrombi and MPGN-like lesions in a patient with angioimmunoblastic T-Cell lymphoma.
  • A 70-year-old man with angioimmunoblastic T-cell lymphoma developed acute renal failure.
  • These findings suggest that cryoglobulin, which consists of monoclonal IgM-lambda, induced glomerular thrombi and acute renal failure in a patient with angioimmunoblastic T-cell lymphoma.
  • [MeSH-major] Immunoblastic Lymphadenopathy / complications. Lymphoma, T-Cell / complications. Thrombosis / etiology. Thrombosis / immunology

  • MedlinePlus Health Information. consumer health - Blood Clots.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16797380.001).
  • [ISSN] 1523-6838
  • [Journal-full-title] American journal of kidney diseases : the official journal of the National Kidney Foundation
  • [ISO-abbreviation] Am. J. Kidney Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin M
  •  go-up   go-down


92. Iqbal MH, Smith PR, Bande S: Chylothorax due to angioimmunoblastic T-cell lymphoma. Intern Med J; 2009 Jan;39(1):67-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chylothorax due to angioimmunoblastic T-cell lymphoma.
  • [MeSH-major] Chylothorax / etiology. Immunoblastic Lymphadenopathy / complications. Lymphoma, T-Cell / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19290988.001).
  • [ISSN] 1445-5994
  • [Journal-full-title] Internal medicine journal
  • [ISO-abbreviation] Intern Med J
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Australia
  •  go-up   go-down


93. Liao YL, Chang ST, Kuo SY, Lin SH, Chen CK, Chang KM, Chuang SS: Angioimmunoblastic T-cell lymphoma of cytotoxic T-cell phenotype containing a large B-cell proliferation with an undersized B-cell clonal product. Appl Immunohistochem Mol Morphol; 2010 Mar;18(2):185-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma of cytotoxic T-cell phenotype containing a large B-cell proliferation with an undersized B-cell clonal product.
  • Angioimmunoblastic T-cell lymphoma is a nodal peripheral T-cell lymphoma considered to be derived from CD4 follicular helper T cells.
  • We presented the case of a 60-year-old male patient with angioimmunoblastic T-cell lymphoma, in which the neoplastic T cells expressed CD8, bcl-6, and programmed death-1.
  • The results of T-cell receptor gene rearrangement study using the Biomed-2 protocols showed clonal rearrangement with amplicons falling within the expected size ranges.
  • Through cloning, sequencing, and BLAST searches, we confirmed that the FR2/JH amplicon was derived from the IgH rearrangement with a deletion of a short segment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19956067.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD8; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Apoptosis Regulatory Proteins; 0 / BCL6 protein, human; 0 / DNA Primers; 0 / DNA-Binding Proteins; 0 / ICOS protein, human; 0 / Inducible T-Cell Co-Stimulator Protein; 0 / PDCD1 protein, human; 0 / Programmed Cell Death 1 Receptor
  •  go-up   go-down


94. Sellier S, Levesque H, Courville P, Joly P: [Cyclophosphamide-induced neutrophilic disease in a patient with angioimmunoblastic lymphadenopathy and myelodysplastic syndrome]. Ann Dermatol Venereol; 2006 May;133(5 Pt 1):459-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cyclophosphamide-induced neutrophilic disease in a patient with angioimmunoblastic lymphadenopathy and myelodysplastic syndrome].
  • [Transliterated title] Dermatose neutrophilique, au décours d'une lymphadénopathie angio-immunoblastique, avec dysmyélopoïèse induite par le cyclophosphamide.
  • BACKGROUND: Cutaneous involvement in patients with angioimmunoblastic lymphadenopathy is often poorly specific for maculopapular eruptions.
  • We report an atypical case of neutrophilic disorder associating subcorneal pustules and hypodermal nodules in a male patient with angioimmunoblastic lymphadenopathy.
  • CASE REPORT: A 62 year-old man with angioimmunoblastic lymphadenopathy was treated with oral prednisone (15 mg/day) and cyclophosphamide.
  • Biopsy of these lesions showed an infiltration of neutrophil polymorphonuclears in the median and superficial dermis with a subcorneal pustule and nodular infiltration of neutrophil polymorphonuclears in the deep dermis and hypodermis respectively.
  • DISCUSSION: This atypical case of neutrophilic disorder associating acute subcorneal pustules and deep dermal-hypodermal nodules seems to correspond to a unique type of neutrophilic disorder that differs from those previously reported in the literature.
  • Neutrophilic disorders have been reported only rarely in patients with angioimmunoblastic lymphadenopathy.
  • [MeSH-major] Cyclophosphamide / adverse effects. Immunoblastic Lymphadenopathy / drug therapy. Immunosuppressive Agents / adverse effects. Neutrophil Infiltration. Skin Diseases, Vesiculobullous / immunology

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16760835.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Immunosuppressive Agents; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


95. Jayaraman AG, Cassarino D, Advani R, Kim YH, Tsai E, Kohler S: Cutaneous involvement by angioimmunoblastic T-cell lymphoma: a unique histologic presentation, mimicking an infectious etiology. J Cutan Pathol; 2006 Sep;33 Suppl 2:6-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous involvement by angioimmunoblastic T-cell lymphoma: a unique histologic presentation, mimicking an infectious etiology.
  • Angioimmunoblastic T-cell lymphoma (AILT) is an aggressive peripheral T-cell lymphoma that is frequently accompanied by a cutaneous eruption.
  • Here, we review the previously reported histologic patterns and present a case of AILT involving the skin with a unique histologic appearance of necrotizing granulomas with abundant histiocytes and eosinophils, mimicking an infectious etiology.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell, Peripheral / pathology. Skin Diseases, Infectious / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Biopsy, Fine-Needle. Diagnosis, Differential. Humans. Lymph Nodes / pathology. Male. Middle Aged


96. Longhi MS, Mitry RR, Samyn M, Scalori A, Hussain MJ, Quaglia A, Mieli-Vergani G, Ma Y, Vergani D: Vigorous activation of monocytes in juvenile autoimmune liver disease escapes the control of regulatory T-cells. Hepatology; 2009 Jul;50(1):130-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vigorous activation of monocytes in juvenile autoimmune liver disease escapes the control of regulatory T-cells.
  • Studies in AIH have focused on autoreactive CD4 and CD8 T cells and impairment of CD4+CD25+ regulatory T cells (T-regs), whereas little is known about the role of monocytes and their relationship with T-regs.
  • We have investigated 51 patients with autoimmune liver disease (AILD) and 27 healthy subjects, finding that monocytes were higher in number (P = 0.044), had a more vigorous spontaneous migration (P < 0.0005 in patients with inactive disease [ID], and P < 0.001 in those with active disease [AD]), displayed a higher tumor necrosis factor alpha (TNF-alpha) over interleukin (IL)-10 production (P = 0.07 in ID and P = 0.0005 in AD), and expressed higher levels of Toll-like receptor (TLR) 4 (P = 0.048 in ID and P = 0.03 in AD).
  • Addition of conventional T-regs (cT-regs) in AILD enhanced monocyte migration (P = 0.05 in ID and P = 0.08 in AD), magnified TNF-alpha over IL-10 production (P = 0.0005 in ID and P = 0.006 in AD), and markedly increased TLR4 expression levels (P = 0.01 in ID and P = 0.004 in AD), whereas in normal subjects it either restrained or left unchanged monocyte function.
  • Addition of tT-regs to monocytes decreased monocyte migration (P = 0.03) and promoted IL-10 production (P = 0.009), leaving unchanged TLR4 expression in healthy subjects, whereas in patients with AILD it induced only a marginal increase in IL-10 production (P = 0.045 in ID and P = 0.13 in AD).
  • CONCLUSION: Monocyte overactivation and inability of cT-regs and tT-regs to restrain it may contribute to the loss of immune tolerance and perpetuation of the autoimmune attack in AILD.
  • [MeSH-major] Autoimmune Diseases / immunology. Leukocytes, Mononuclear / physiology. Liver Diseases / immunology. T-Lymphocytes, Regulatory / physiology

  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19437492.001).
  • [ISSN] 1527-3350
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


97. Yamane A, Awaya N, Shimizu T, Ikeda Y, Okamoto S: Angioimmunoblastic T-cell lymphoma with polyclonal proliferation of plasma cells in peripheral blood and marrow. Acta Haematol; 2007;117(2):74-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma with polyclonal proliferation of plasma cells in peripheral blood and marrow.
  • [MeSH-major] Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell / pathology. Plasma Cells / pathology

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17106190.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 130068-27-8 / Interleukin-10
  •  go-up   go-down


98. Tzankov AS, Went PT, Münst S, Papadopoulos T, Jundt G, Dirnhofer SR: Rare expression of BSAP (PAX-5) in mature T-cell lymphomas. Mod Pathol; 2007 Jun;20(6):632-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare expression of BSAP (PAX-5) in mature T-cell lymphomas.
  • Lineage determination in lymphomas is based on the assessment of lineage-specific markers, such as the B-cell-specific activator protein of the paired box family (BSAP, PAX-5) for the B-cell lineage.
  • BSAP is thought to be expressed exclusively in B cells from the pro-B- to the mature B-cell stage and then silenced in plasma cells.
  • BSAP has oncogenic potential and experimental evidence shows that the T-cell lineage is prone to this effect.
  • Herein, we report on a BSAP-positive peripheral T-cell lymphoma with monoclonal T-cell receptor gamma-gene rearrangement.
  • To assess the relative frequency of BSAP expression in mature T-cell lymphomas, we constructed and examined a tissue microarray consisting of 43 angioimmunoblastic T-cell lymphomas and peripheral T-cell lymphomas and detected no additional BSAP-positive cases.
  • To conclude, BSAP can probably contribute to T-cell lymphomagenesis not only in vitro, but also in vivo.
  • It is rarely expressed in peripheral T-cell lymphoma, thus its detection on lymphoid malignancies cannot be considered definitively lineage specific.
  • [MeSH-major] B-Cell-Specific Activator Protein / biosynthesis. Lymphoma, T-Cell / metabolism
  • [MeSH-minor] Aged. Biomarkers, Tumor / biosynthesis. Cell Lineage. Female. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Humans. Lymphoma, T-Cell, Peripheral / metabolism. Male. Middle Aged. Tissue Array Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17431414.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / Biomarkers, Tumor; 0 / PAX5 protein, human
  •  go-up   go-down


99. de Leval L, Gisselbrecht C, Gaulard P: Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br J Haematol; 2010 Mar;148(5):673-89
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in the understanding and management of angioimmunoblastic T-cell lymphoma.
  • Angioimmunoblastic T-cell lymphoma (AITL) is a distinct peripheral T-cell lymphoma (PTCL) entity with peculiar clinical and pathological features.
  • The recent identification of follicular helper T (T(FH)) cell as the cell of origin of this neoplasm represents a major step in our understanding of the pathobiological characteristics of the disease and should, in the future, clarify the diagnostic criteria for AITL and help to delineate its spectrum, especially from PTCL, not otherwise specified (PTCL, NOS).
  • Deciphering the pathogenesis of the disease is needed to identify targets for new therapies that are expected to improve the poor outcome of AITL patients, when treated with conventional chemotherapy regimens.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / physiopathology
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Cytogenetics. Diagnosis, Differential. Humans. Immunophenotyping. Prognosis. T-Lymphocytes, Helper-Inducer / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19961485.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 170
  •  go-up   go-down


100. Valbuena JR, Rassidakis GZ, Lin P, Atwell C, Georgakis GV, Younes A, Jones D, Medeiros LJ: Expression of heat-shock protein-90 in non-Hodgkin's lymphomas. Mod Pathol; 2005 Oct;18(10):1343-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of heat-shock protein-90 in non-Hodgkin's lymphomas.
  • Heat-shock protein-90 (HSP90) inhibitors are currently being used in phase I clinical trials for treating patients with a variety of neoplasms including lymphomas.
  • Using immunohistochemical methods, we assessed for HSP90 expression in 412 cases of non-Hodgkin's lymphoma.
  • In B-cell lymphomas, HSP90 was moderately to strongly expressed in all cases of Burkitt's lymphoma (5/5, 100%), and in subsets of follicular lymphoma (17/28, 61%), diffuse large B-cell lymphoma (27/46, 59%), nodal marginal zone B-cell lymphoma (6/16, 38%), plasma cell neoplasms (14/39, 36%), small lymphocytic lymphoma/chronic lymphocytic leukemia (3/9, 33%), mantle cell lymphoma (12/38, 32%) and lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia (3/10, 30%).
  • HSP90 was weakly expressed in six of 14 (43%) cases of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.
  • In T-cell lymphomas, HSP90 was moderately to strongly expressed in subsets of anaplastic large-cell lymphoma (14/24, 58%; 9/12 ALK+ and 5/12 ALK-), precursor-T-cell lymphoblastic leukemia/lymphoma (20/65, 31%), unspecified peripheral T-cell lymphoma (8/43, 23%) and angioimmunoblastic T-cell lymphoma (2/17, 12%).
  • We conclude that HSP90 is commonly expressed in a subset of many types of B- and T-cell lymphoma.
  • These data suggest that many lymphoma types are suitable targets for modulation of HSP90 activity, and that HSP90 inhibitors are a potential investigational therapy for lymphoma patients.
  • [MeSH-major] HSP90 Heat-Shock Proteins / biosynthesis. Lymphoma, Non-Hodgkin / metabolism
  • [MeSH-minor] Cell Line, Tumor. Humans. Lymph Nodes / metabolism. Lymphoma, B-Cell / metabolism. Lymphoma, T-Cell / metabolism

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16056252.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HSP90 Heat-Shock Proteins
  •  go-up   go-down






Advertisement